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Dengue virus (DENV) is the causative agent for dengue fever and the more severe 
dengue haemorrhagic fever / dengue shock syndrome which could result in death. 
Currently, with no effective vaccines or anti-virals available, 2.5 billion of the world’s 
population is constantly at risk of DENV infection. In this study, a 384-well high-
throughput RNAi-based screening platform was developed to screen genomic 
libraries for host factors that could modulate the replication of DENV in host cells. 
The application of the developed RNAi-based screening platform on a library of 
human protein hydroxylases established the association between hypoxia and the 
replication of DENV. Furthermore, this study has also shown for the first time, that 
replication of DENV2 could be modulated via the hypoxic pathway by hypoxic-
inducible factors (HIFs). Finally, an expression study of the transcripts centered on 
the NF-kB pathway by PCR array revealed that the activation of the hypoxia-
inducible pathway by HIFs resulted in an up-regulation of expression in the type 1 
interferons (α and β), which is likely to intervene in the replication of DENV2 in HuH-7 
cells. 





1.1 DENGUE VIRUS 
 
Dengue virus (DENV) is a small, enveloped, positive-sense, single-stranded RNA 
virus that is classified under the Flavivirus genus. Viruses belonging to the 
Flaviviridae family are transmitted amongst humans through vectors, with DENV 
particularly transmitted via the bite of the mosquito species, Aedes albopictus and 
Aedes aegypti [Thomas et al., 2003]. DENV is the causative agent for the febrile 
dengue fever (DF) and the more severe life-threatening dengue haemorrhagic fever 
(DHF) or dengue shock syndrome (DSS) [Gubler, 1998]. Currently, there are four 
distinct serotypes of DENV (DENV1-4) and infection from one of the serotype does 
not confer immunity against the three other serotypes. It has been estimated that 
there are approximately 50-100 million cases of DF and 250,000-300,000 cases of 
DHF/DSS occurring yearly worldwide. Due to the lack of effective vaccine and anti-
viral treatment, 2.5 billion people are currently at risk for DENV infection in the 
subtropical and tropical regions of the world [Clyde et al., 2006]. 
 
In humans, DENV has been shown to primarily target cells of the mononuclear 
phagocytic lineage which includes cells like monocytes, macrophages and dendritic 
cells [Jessie et al., 2004]. Due to inconclusive evidence, it is still debatable whether 
hepatocytes, lymphocytes, endothelial cells as wells as neuronal cells are 
susceptible to DENV infection. However, in-vitro propagation of DENV in continuous 
cell lines of similar lineages has been demonstrated with production of virus titer as 
high as 106 PFU/ml. 
 
The RNA genome of DENV closely resembles that of a host cellular mRNA, which 
consist of a 5’ 7-methyl guanosine cap, a 5’ un-translated region (UTR), a single 
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open reading frame (ORF) encoding for a single polyprotein and a 3’ UTR (Figure 
1.1). The only difference from a cellular mRNA is the lack of a polyadenylated (poly 
A) 3’ end. However despite the absence of the poly A tail, the DENV RNA is still able 
to utilize the same translational mechanism as host cellular mRNA. 
 
The replication cycle of DENV begins with the stages of adsorption and entry. Upon 
binding to the host cell surface receptor, entry into host cell is achieved 
predominately via the receptor-mediated endocytosis (RME). Among the several 
candidate receptors reported, such as heparan sulfate [Chen et al., 1997], heat 
shock protein 70 (Hsp70), heat shock protein 90 (Hsp90) [Valle et al., 2005], GRP78 
(BiP) [Jindadamrongwech et al., 2004], CD14 [Chen et al., 1999], 37-kDa/67-kDa 
high affinity laminin receptor [Thepparit and Smith, 2004], and liver/lymph node-
specific intercellular adhesion molecule 3 (ICAM-3)-grabbing non-integrin, it is the 
DC-specific (ICAM)-3-grabbing non-integrin (DC-SIGN) that has shown to be the 
most promising as the receptor in which DENV binds to [Tassaneetrithep et al., 
2003]. Under low pH condition within the endosomes, the virus envelope protein then 
fuses to the membrane of the late endosomes, resulting in the release of the viral 
RNA into the cytoplasm for replication [Kimura and Ohyama, 1988; Guirakhoo et al., 
1989]. 
 
Following the adsorption and entry of DENV is primary translation and early viral 
RNA replication. The viral RNA not only serves as a template for translation of viral 
proteins but also for the replication of RNA genome for progeny virus. Hence, the 
translation of the viral RNA must first be carried out to produce the viral RNA 
polymerase (NS5) required for downstream replication processes [Grun and Brinton, 
1987]. NS5 along with the other six non-structural proteins (NS1, NS2A, NS2B, NS3, 
NS4A, NS4B) and three structural proteins, capsid, pre-membrane and envelope (C, 
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prM, E) are encoded within an ORF and translated as a large precursor polyprotein 
[Hahn et al., 1988]. 
 
The individual viral proteins are subsequently cleaved by co-translational proteolytic 
processes [Rice et al., 1985], and signal sequences within the polyprotein dictates 
the translocation of prM, E and NS1 proteins to the lumen of the endoplasmic 
reticulum (ER) [Mackenzie et al., 1999]. The remaining viral proteins C, NS3 and 
NS5 are localized within the cytoplasm while the majority of NS2A/B and NS4A/B 
remain as transmembrane proteins. It is postulated that processing of the polyprotein 
is likely to be by a combination of viral NS3 protein together with its cofactor NS2B 
protein as well as host signalases. Host signalases that are found within the lumen of 
the endoplasmic reticulum are shown to be responsible for cleavage at the N-
terminals of prM, E, NS1 and NS4b proteins [Mackow et al., 1987; Chambers et al., 
1989]. These evidences are further supported by the fact that cellular membranes 
are required for the co-translational proteolytic processes [Markoff, 1989; Nowak et 
al., 1989]. Cleavage of the other viral proteins: M, NS2A/B, NS3, NS4A and NS5 by 
non-signalase proteases and viral NS2B-NS3 proteins have also been identified 
[Biedrzycka et al., 1987; Speight et al., 1988; Falgout et al., 1991]. 
 
Once the viral polymerase has been translated, RNA replication is initiated. Every 
virus has only one copy of RNA, which is used as a template for both the translation 
of viral proteins as well as genome replication for progeny viruses. Since both 
processes cannot occur concurrently, DENV has adopted a replication strategy 
where after translation of the input RNA strand has been completed, the virus 
switches to synthesize the negative-strand RNA templates to generate new positive-
strand RNA. This strategy allows for excess production of the positive-strand RNA to 
cope with its production of viral genome for assembly as well as viral mRNA for 
polypeptide translation. 












Figure 1.1: Arrangement of the dengue virus RNA genome. Dengue RNA consists of a single 
open reading frame flanked by 5’ and 3’ un-translated regions. Highly conserved secondary 
structures are found within the un-translated regions and play functional role at various stages 
of the viral replication cycle. (Source: Clyde et al., 2006) 
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There is evidence suggesting that the conserved sequences and secondary 
structures within 5’ and 3’ UTR of the viral RNA play an important role in regulating 
the synthesis of progeny viral RNA [Holden et al., 2006]. Besides regulating the viral 
RNA synthesis, 5’ and 3’ UTR are also involved in the generation of newly 
synthesized positive-strand viral RNA by means of circularization of the viral RNA to 
form a more stable RNA replication complex [You and Padmanabhan, 1999; You et 
al., 2001]. More recently, structural studies also suggested that the cis-trans activity 
of the viral protease (NS3) and its cofactor (NS2B) may play a pivotal role in 
controlling the balance between viral protein translation and RNA replication by 
controlling the availability of processed viral proteins [Erbel et al., 2006]. Evidence 
provided by Aleshin et al (2007) has stressed the importance of NS2B protein as it 
“wraps” around the proteases domain of NS3 protein to form an integral part of the 
protease active site. 
 
The final phase of DENV replication is the assembly and release of progeny DENV 
from the host cell. Nucleocapsids are first assembled from the C proteins and viral 
RNA genome followed by the budding of these nucleocapsids through intra-
cytoplasmic membrane containing integral E and prM proteins to form the viral 
envelope [Russel et al., 1980]. Through the combination of cryo-electron microscopy 
and X-ray crystallography, it was revealed that different states of E and prM proteins 
result in the assembled DENV existing as immature and mature forms in the 
cytoplasm [Li et al., 2008; Yu et al., 2008]. The transformation of the immature viron 
to the mature form most probably occurs while in transition through the secretory 
trans-Golgi network (TGN). The observed morphological changes resulted from 
structural changes to the E protein is triggered by low pH (5.8–6.0) and occurs before 
the cleavage of prM by a host encoded furin protease [Zhang et al., 2004].  
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The final process would be the release of the progeny virus from the host cell via 
secretory exocytosis as assembled virons within secretory vesicles fuse with the host 
cell plasma membrane [Hase et al., 1987]. Since the released viruses contain almost 
no prM protein, the cleavage of the prM protein also occurs during the secretory 
process through the TGN. It was shown that the final maturation cleavage of stable 
prM to M is achieved by host furin protease [Stadler et al., 1997; Elshuber and 
Mandl, 2005]. The cleavage results in the reorganization of the virus surface protein 
by converting the prM-E protein heterodimers to E protein trimers [Wengler and 
Wengler, 1989; Randolph et al., 1990], which makes the progeny virus competent for 
infection. 
 
1.1.1 DENGUE VIRUS AND THE HOST INNATE IMMUNITY 
 
Interferons (IFN-α, IFN-β and IFN-γ) are a multi-gene family of cytokines that can 
profoundly affect a wide variety of functions in animal cells including virus replication, 
cell growth and differentiation, and the immune response. Like all viral infections, the 
host’s innate immune system plays an important role in the prognosis of DENV 
infection. 
 
IFN-α/β play important roles in the inhibition of viral replication through the induction 
of RNA-dependent protein kinase (PKR), which functions to induce post-translational 
modifications such as protein phosphorylation to modify the functional activity of 
proteins [Diamond and Harris, 2001]. Hence, it is not surprising that DENV have 
evolved to inhibit IFN-α signaling by means of reducing the signal transducer and 
activator of transcription 2 (STAT2) with NS4B and possibly NS2A proteins as the 
antagonist [Jones et al., 2005]. IFN-γ on the other hand, participates in clearance of 
viral infection through the activation of macrophages to produce nitric oxide (NO). 
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Strong evidence showing that NO is able to inhibit the replication DENV in-vitro has 
been presented in the work of Charnsilpa et al (2005). 
 
It has been shown that IFN-α, IFN-β and IFN-γ offer resistance against in-vitro DENV 
infection. However, this mode of protection is only effective as a prophylactic 
approach [Diamond et al., 2000; Ho et al., 2005]. The ability of IFN in protection 
against DENV infection has also been demonstrated in mice deficient for receptors of 
both IFN-α/β and IFN-γ [Johnson and Roehrig, 1999; Shresta et al., 2004]. 
 
Correspondingly, in clinical studies conducted in India [Chakravarti and Kumaria, 
2006], Thailand [Kurane et al., 1991; Kurane et al., 1993], Taiwan [Chen et al., 2005; 
Chen et al., 2006], and Vietnam [Hguyen et al., 2004], all reported measuring higher 
levels of IFNs in subjects with DF and DHF/DSS when compared to healthy 
individuals. The most interesting findings were presented by the Taiwanese group 
where elevated levels of circulating IFN-γ were detected in survivors of DF and DHF 
when compared to non-survivors which did not exhibit any increase [Chen et al., 
2006]. 
 
These clinical findings in concert with earlier in-vitro and animal models seem to 
implicate IFN levels in the protective response against disease severity in DENV-
infected host. 
 
1.1.2 DENGUE VIRUS AND THE HOST ADAPTIVE IMMUNITY 
 
The adaptive immunity has been hypothesized to act as a double-edged sword 
during DENV infection. Since there are four serotypes of DENV, infection by one 
DENV serotype only confers adaptive immunity towards that particular serotype. This 
serotype specific immunity is due to production of neutralizing antibodies by memory 
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B-cells. Over time, much effort has been centered on the identification of epitopes 
capable of producing neutralizing antibodies against DENV. Antibodies against E, 
prM and NS1 proteins have proved to be effective in neutralizing DENV both in-vitro 
and in-vivo [Kaufman et al., 1987; Henchal et al., 1988;  Kaufman et al., 1989; Wu et 
al., 2003]. 
 
By far, the DENV protein most widely accepted to encompass neutralizing epitopes 
would be the E glycoprotein, with the focus of many research groups on defining 
cross-reactive neutralizing epitope within the E protein for vaccine development as 
well as monoclonal antibodies for therapeutics. Of the three domains within the E 
protein, domain III presents itself as the most promising region for the identification of 
neutralizing epitopes, with the most extensively characterized monoclonal antibody 
4E11, binding to domain III of DENV1 [Bedouelle et al., 2006]. Monoclonal antibodies 
directed against an epitope mapped to domain II of E protein have also shown cross 
protection against all serotypes [Crill and Chang, 2004]. 
 
On the other hand, antibodies have also been hypothesized to be risk factors 
involved in exacerbating disease during DENV infection. It was proposed that 
antibody dependent enhancement (ADE) is responsible for the manifestation of 
DHF/DSS in patients exposed to a second infection by a different DENV serotype 
from that of the previous infection. The ADE model hypothesizes that DENV-specific 
antibodies, due to cross reactivity from previous DENV infection or sub-neutralizing 
levels of serotype specific antibodies, are able to interact with DENV but not 
neutralizing it. This instead allows for increased virus uptake into target cells via the 
Fcγ receptors which are found on the surface of monocytic cells [Halstead, 2003]. 
 
Not only is the humoral arm hypothesized to contribute to DENV pathogenesis, 
enhancement of T cell-mediated immune responses during heterologous secondary 
Chapter 1: Introduction 
 9 
infections are recently proposed to increase cytokine and chemokine production, 
resulting in a cytokine storm. This wave of cytokine action is believed to enhance 
vascular permeability, contributing to the pathogenesis of DHF/DSS [Basu and 
Chaturvedi, 2008]. Indeed, this postulation is supported by elevated levels of pro-
inflammatory cytokines IFN-γ, TNF-α, IL-10 levels in sera of DHF/DSS patients. 
[Chaturvedi et al., 2000, 2007]. 
 
Other mechanisms such as autoimmune responses against the cross-reactive 
components of dengue viruses can induce platelet lysis and nitric oxide mediated 
apoptosis of endothelial cells, contributing to thrombocytopenia and vascular 
damage. Genetic susceptibility of host genetic factors to DENV infection as well as 
the virus virulence factors are also proposed to be risk factors for severe dengue 
infection [Halstead, 2007]. 
 
1.2 RNA INTERFERENCE (RNAI) 
 
In 1998, Fire and Mello discovered a novel endogenous gene silencing pathway that 
is found in all eukaryotic cells. Their discovery was one which overturned 
contemporary scientific understanding of how post-transcriptional genetics could be 
regulated, so much that it reshaped the landscape of scientific research. This 
discovery of gene silencing by double-stranded RNA (dsRNA) in Caenorhabditis 
elegans clinched them the Nobel Prize in 2006 [Fire et al., 1998]. 
 
Traditionally, it was thought that prevention of protein translation was achieved by 
mRNA silencing, induced by the annealing of an anti-sense RNA to targeted mRNA 
based on the canonical Watson-Crick base pairing. What Fire and Mello (1998) had 
discovered was an evolutionarily conserved pathway known as RNA interference 
(RNAi) mediated by small RNAs. Over the years, it was discovered that there exists 
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many forms of small RNAs which can mediate gene regulation at the post-
transcriptional level. These small RNAs include the small-interfering RNA (siRNA), 
microRNA (miRNA) and the more recently discovered Piwi-interacting RNA (piRNA) 
and repeat associated small interfering RNA (rasiRNA) [Vagin et al., 2006; Faehnle 
and Joshua-Tor, 2007]. 
 
1.2.1 SMALL-INTERFERING RNA (SIRNA) 
 
The RNAi pathway is triggered by dsRNA suggesting that RNAi is an ancient 
pathway which traditionally exists to protect the cell from foreign RNAs, such as 
viruses. In the RNAi pathway, long exogenous dsRNA are cleaved into smaller 
siRNAs by an enzyme known as Dicer, a ribonuclease belonging to the dsRNA 
specific RNase III family (Figure 1.2) [Bernstein et al., 2001]. siRNA produced by the 
Dicer protein consist of two 21-nucleotide long RNA with a 5’ phosphate end and a 3’ 
hydroxyl end. The two strands of RNA have 19-nucleotides which are complementary 
from the 5’phosphate ends, hence when annealed together, leave 2-nucleotide 
overhangs at both the 3’ hydroxyl ends [Zamore et al., 2000; Elbashir et al., 2001a]. 
Of the two strands, it is the guide strand that will direct silencing whereas the 
passenger strand will be destroyed subsequently [Elbashir et al., 2001b]. The guide 
strand then regulates the target mRNA via the RNA-induced silencing complex 
(RISC) which comprises of the core Argonaute protein (AGO) as well as other 
auxiliary proteins by cleaving the target mRNA at the phosphodiester bond between 
nucleotides 10 and 11 of the guide strand [Hammond et al., 2000; Elbashir et al., 
2001]. 
 
The identity of both the guide strand and passenger strand is determined by the 
thermodynamic stability of the 5’ phosphate ends of both the siRNA strand [Khvorova 
et al., 2003; Schwarz et al., 2003]. 







Figure 1.2: The pathway of RNA interference. Firstly, dsRNAs are processed into 21-23 
nucleotide siRNAs by an enzyme called Dicer. Next, the siRNAs are assembled into 
endoribonuclease-containing complex known as RNA-induced silencing complex (RISC) with 
the help of axullary proteins such as R2D2. The mature RISC then utilizes the guide strand 
siRNA to target complementary mRNA where it is cleaved to prevent translation of the 
protein. (Source: Ambion Inc, Applied Biosystems) 
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The difference in thermodynamic stability is detected by the dsRNA binding protein 
R2D2, the partner of Dicer as well as part of the RISC loading complex (RCL) [Liu et 
al., 2003]. RCL plays a bridging role between the Dicer and RISC by recruiting the 
AGO and transfers the siRNA duplex into pre-RISC. Once inside the pre-RISC, AGO 
then proceeds to cleave the passenger strand before releasing it from RISC [Kim et 
al., 2006; Leuschner et al., 2006]. The successful release of the passenger strand 
from pre-RISC then converts it into the mature RISC which contains only the guide 
strand siRNA [Matranga et al., 2005; Rand et al., 2005]. 
 
1.2.2 MICRORNA (MIRNA) 
 
Eukaryotic cells also contain endogenous small RNAs that function to regulate gene 
expression at the post-transcriptional level. miRNAs are derived from precursor 
molecules known as primary miRNAs (pri-miRNAs). These pri-miRNAs encode for a 
cluster of miRNAs and are transcribed by RNA polymerase II (RNA Pol II) from the 
genome [Lee et al., 2004b]. The pri-miRNA will be processed into a 20-24 nucleotide 
long miRNA. 
 
After its transcription, the pri-miRNA, which is present in the nucleus, is processed 
into a 60-70 nucleotide long pre-miRNA by the enzyme Drosha and its partner 
DGCR8 which contain a dsRNA binding domain [Han et al., 2004; Lee et al. 2004a]. 
The processed pre-miRNA then forms a hairpin loop flanked by complementary base 
pairs that forms a stem [Denli et al., 2004]. The stem looped pre-miRNA is then 
exported out of the nucleus by the nuclear export protein, Exportin 5 [Bohnsack et al., 
2004]. Once in the cytoplasm, the Dicer then cleaves the pre-miRNA to generate a 
RNA duplex containing the miRNA and miRNA* [Chendrimada et al., 2005]. 
Interestingly, it is the same thermodynamic stability principle of the guide and 
passenger strand siRNA which determines which miRNA or miRNA* strand ends up 
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as the guide strand for post-transcriptional gene regulation [Khvorova et al., 2003; 
Schwarz et al., 2003]. 
 
In mammalian cells, most miRNAs do not base pair completely with their intended 
mRNA targets. Binding only occurs within a limited number of nucleotides at the 5’ 
phosphate end of the miRNA, also known as the “seed” region [Brennecke et al., 
2005]. The limited base pairing of the “seed” region, which determines target 
selection, is less specific when compared to the guide strand of the siRNA where 
complete base pairing of all nucleotides are achieved. However, it is also the small 
size of the “seed” which increases the sensitivity. Hence, a single miRNA can 
regulate many more genes at the post-transcriptional level as compared to siRNAs 
[Baek et al., 2008; Selbach et al., 2008]. 
 
miRNAs function like transcription factors to regulate diverse cellular pathways that 
range from housekeeping functions to cellular responses towards extracellular stress. 
Hence, miRNAs are found only in specific tissue and cells, and function in specific 
biological processes only at specific times [Landgraf et al., 2007]. 
 
1.2.3 DELIVERY OF SIRNA 
 
In order for RNAi to be effective in eliciting gene knock-down in experimental 
approaches, siRNA must first be delivered into the cytoplasm of a target cell in which 
the machinery of the RNAi pathway exists. Although direct introduction of naked 
siRNAs to cells has been shown to be possible [McCaffrey et al., 2002], this method 
of delivery is generally ineffective due to the presence of RNA degrading enzymes 
(RNase), which would quickly degrade the RNA molecules. As a result, high 
concentrations of siRNAs would have to be used in order to ensure effective gene 
knock-down. 
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An alternative approach is to modify the siRNA chemically to increase its stability 
against RNases. The most common approach to modify the siRNA would be the 
addition of residues to the 2’ position of the ribose. Reports have shown that the 2’-
OH residue is not required for the silencing function of siRNA [Chiu and Rana, 2003]. 
Hence, by replacing the 2’-OH with residues like 2’-deoxyfluoridine (2’-F), siRNA was 
found to have better stability while still retaining activity [Layzer et al., 2004]. The 
integration of locked nucleic acid (LNA) residues to both ends of the siRNA or 
replacing the phosphodiester linkages between the nucleotides with phosphothioates 
(PS) have been also shown to increase the half-life of the siRNA [Crooke, 2000]. 
While the aim of chemically modifying siRNA is to increase RNA stability, it is 
possible that bulkiness resulting from some modifications may interfere with 
unwinding of the siRNA duplex or integration of the guide strand into the RISC 
[Prakash et al., 2005]. 
 
siRNA are unable to pass through the cell membrane readily by diffusion because of 
the highly negatively charged nature of the nucleic acid. Beside chemically modifying 
the siRNA to increase its the stability, a carrier system can be deployed not only to 
physically protect the siRNA from degradation by RNase but also to facilitate its 
uptake into cells [Zabner et al., 1995; Simoes et al., 1999]. This method of delivery is 
known as transfection and the most widely used transfection agents usually contain 
cationic component for binding to the siRNA. The cationic compound, either in the 
form of cationic lipid, cationic peptide or cationic polymer surrounds the siRNA and 
enters the cell through clathrin-mediated endocytosis [Zuhorn et al., 2002]. Recently, 
findings by Lu et al (2009) have shown that although the cationic-siRNA complexes 
enter the cell via endocytosis, the majority of siRNA remains in the endo-lysosomes. 
Hence, it is the direct fusion of the cationic lipids with the plasma membrane which 
successfully delivers the siRNA into the cytoplasm to activate RNAi. 
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Another method to deliver siRNA into cells is the use of viral vectors, which can 
efficiently infect specific host cells and transfer genes into host genome 
(transduction). Currently, there are five types of viral vectors that are commonly used, 
namely; adenovirus, adeno-associated virus, baculovirus, lentivirus and retrovirus. By 
the process of transduction, DNA encoding for precursors of siRNA can be 
transferred into specific host cells, hence solving the problem of insufficient 
concentration of siRNA by stable gene expression to carry out gene silencing in 
some of the viral delivery systems. The presence of siRNA in the precursor form also 
allows the siRNA to be incorporated further upstream of RNAi pathway, hence 
ensuring efficient delivery of the guide strand into RISC [Anson, 2004]. 
 
1.3 GENETIC SCREENING WITH RNAI 
 
Not only has RNAi accelerated the understanding and discovery of many new gene 
functions, the versatility of its application has also opened up many novel research 
opportunities in the field of biology. The versatility of RNAi to target almost any gene 
and its ability to knock-down the targeted gene with high specificity is the main 
reason why RNAi has been used widely for studying gene function. RNAi was initially 
utilized to knock-down function of individual genes for genetic study. Subsequently, 
the creation of RNAi libraries has allowed genome-wide loss of function screening. 
The use of RNAi for screening has been made easier with the completion of the 
human genome project where genes of all known proteins have been identified and 
mapped, thus allowing for creation of more focused RNAi screening libraries. 
 
To date, several studies using RNAi as the screening platform have been completed 
and yielded interesting results. Hao et al (2008) performed a genome-wide RNAi 
screen against 13,071 Drosophila genes to identify host genes important for 
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replication of influenza virus. From this study, over 100 genes when silenced in 
Drosophila cells could significantly inhibit the replication of a modified influenza virus. 
Further investigation revealed that the human homologues of ATP6V0D1, COX6A1 
and NXF1 have key functions in the replication of H5N1 and H1N1 influenza A 
viruses. 
 
Sessions et al (2009) was able to identify 116 candidate insect host factors required 
for DENV-2 propagation by carrying out a genome-wide RNA interference screen in 
Drosophila melanogaster cells using a well-established 22,632 double-stranded RNA 
library. Of the 116 candidates identified, most of the host factors were newly 
implicated in the propagation of dengue virus, and 82 of the factors had readily 
recognizable human homologues. By using a second targeted short-interfering-RNA 
screen, Sessions et al (2009) showed that 42 of these were human host factors 
essential for DENV infection. 
 
In addition, Azorsa et al (2009) has also made use of RNAi screen to target the 
genes of 572 kinases. Their aim was to identify kinases that when silenced would 
increase the sensitivity of pancreatic cancer cells to gemcitabine, the most widely 
used chemotherapeutic against pancreatic cancer. Analysis of screening results 
indicated checkpoint kinase 1 (CHK1) as a “hit” and subsequent validation assays 
showed that pancreatic cancer cells (MIA PaCa-2 and BxPC3) treated with CHK1-
siRNA exhibited a three to ten-fold decrease in the inhibitory concentration 50% 
(IC50) of gemcitabine versus control siRNA-treated cells or CHK2 siRNA-treated cells. 
 
We have also recently published a study that demonstrated the use of a targeted 
small interfering RNA (siRNA) library to identify and profile key cellular genes 
involved in processes of endocytosis, cytoskeletal dynamics and endosome 
trafficking that are important and essential for DENV infection (Ang et al., 2010). The 
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infectious entry of DENV into Huh7 cells was shown to be potently inhibited by 
siRNAs targeting genes associated with clathrin-mediated endocytosis.  
 
In many aspects, the approaches and considerations in designing an RNAi screening 
assay are very similar to conventional phenotypic screening assays. One of the most 
important aspects in the design of an RNAi screen is the development of a robust 
assay for the primary screen, which is specific to the biological process being 
investigated. The ease of the assay is often inversely proportional to its specificity; 
hence in a large scale RNAi screen, it is necessary to find a balance between 
practicality and specificity [Boutros and Ahringer, 2008].  
 
Recent advancement in the field of imaging at cellular level, when coupled to cell 
culture based screening assays, has lead to a significant increase in the ease and 
throughput of the screening assays. Using high resolution scanner-type image 
capturing devices, magnified images of cells within individual wells can be captured. 
Subsequently, analysis of the captured images using advanced algorithms in cell 
image analysis software such as CellProfilerTM by Broad Institute allows for easy and 
fast identification of hits such as detection and differentiation of different fluorophores 
within cells [Carpenter et al., 2006]. 
 
1.3.1 CONTROLS AND Z FACTOR 
 
The other important aspect to consider for RNAi screen would be the selection of 
positive and negative controls to give a high signal-to-noise ratio, which not only 
allows hits to be identified easily but also provides information pertaining to the 
reproducibility as well as robustness of the screening assay. 
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The sensitivity, reproducibility and accuracy of a high throughput screening (HTS) 
assay can be determined by a screening window coefficient known as the “Z-factor” 
[Zhang et al., 1999]. Since the Z-factor is calculated based on the mean signal and 
signal variation (standard deviation) of the positive and negative controls, it takes into 
account three aspects of a HTS assay: 1) the dynamic range of assay signal, 2) data 
variation associated with sample measurement and 3) data variation associated with 
reference control measurement. Hence, not only can the Z-factor can be used as a 
tool for comparison and evaluation of the robustness of the HTS assay, it can also be 
used as a tool to optimize and validate the HTS assay (Table 1.1). 
 
1.3.2 SECONDARY ASSAYS 
 
Majority of the hits identified by the primary screening assay are defined as “true 
positive” hits. However, it is impossible to rule out the possibility of “false positives”. 
Hence, secondary screening assays are carried out to confirm the validity and 
relevance of the hits. Many types of secondary assays can be carried out to 
distinguish between the “true positives” and “false positives”. 
 
One method to confirm the relevance of the hits is by probing the process using a 
different assay other than the primary assay. Although this method of validation is 
usually more laborious and time consuming, but the results generated are also more 
specific.  
 
Once the assay has been successfully developed, a small “pilot screen” including the 
positive and negative controls is usually done before undertaking a whole genome 
screen. This will ensure that the hit rate is not too high and the screen can be carried 
out in feasible and reproducible manner on a larger scale. 
 









Table 1.1: Formula and categorization of screening assay quality by the value of Z-factor. 
(Source Zhang et al., 1999) 
 
 
, where, p = sample/test and n = control/normal 
 
 
Z-Factor Value  Structure of Assay   Related to Screening 
 
1   SD=0 (no variation),   An ideal assay 
   dynamic range → ∞ 
 
1 > Z ≥ 0.5  Large separation band   An excellent assay 
 
0.5 > Z > 0  Small separation band   A double assay 
 
0   No separation band   A “yes/no” type assay 
   sample and control bands touch 
 
< 0   No separation band   Screening impossible 
   Sample and control bands overlap 
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1.4 PROTEIN HYDROXYLASES 
 
Hydroxylases are a class of enzymes that facilitate hydroxylation, a chemical reaction 
characterized by the introduction of one or more hydroxyl groups (-OH) into a 
compound (or radical) thereby causing oxidation of the compound. In the human 
body, one of the most common hydroxylation processes is carried out on the amino 
acid, proline to hydroxyproline. The formation of hydroxyproline is achieved by 
hydroxylation of the Cγ atom in proline. Hydroxyproline functions as one of the 
building blocks of collagen and is responsible for the formation of collagen helix. 
Proline hydroxylation is also a vital component of the hypoxia response via hypoxia 
inducible factors (HIFs) in which proline is hydroxylated on its Cβ atom. Lysine is also 
another amino acid which may be hydroxylated, and hydroxylation is carried out on 
its Cδ atom, thus forming hydroxylysine which is critical for the cross-linking of stable 
collagen. 
 
These hydroxylations are mainly catalyzed by the large multi-subunit enzymes: prolyl 
4-hydroxylase, prolyl 3-hydroxylase and lysyl 5-hydroxylase, which requires L-
ascorbic acid (vitamin C) as an essential cofactor [Sheldon and Pinnel, 1985]. In 
principle, hydroxylation requires iron, as well as molecular oxygen and α-
ketoglutarate as substrate to carry out the oxidation. Ascorbic acid is used as a 
carrier to return the iron to its oxidized state. Hence, a sign of vitamin C deprivation in 
any individual is the manifestation of the disease Scurvy, which is characterized by 
formation of spots on the skin, spongy gums, and bleeding from the mucous 
membranes. Scurvy is a disease of the connective tissue and arises due to the 
deficiency in the hydroxylation of proline.  
 
 





With 250,000 to 300,000 cases of dengue haemorrhagic fever and dengue shock 
syndrome reported worldwide annually and more than 2.5 billion of the world’s 
population constantly at risk of being infected with dengue virus, there is an urgent 
need to better understand the replication and pathogenesis of dengue virus due to 
the lack of anti-viral therapy and availability of an effective vaccine. Hence, the 
objectives of this project are to: 
 
• Develop a 384-well high-throughput siRNA screening assay which would be 
consistent and highly specific to silence the wide array of human proteins 
libraries, hence making it a suitable platform to screen for host proteins which 
could modulate the replication of not only dengue virus but other RNA viruses 
as well. 
 
• And to use the developed screening assay to screen a small library of human 
protein hydroxylases as the pilot screening. The screening assay would be 
applied on the replication of dengue virus and possibly be able to identify 
candidate hydroxylases which could mediate the replication of dengue virus 
in-vitro. 
 
Hence, with the successful development of the screening assay, a new avenue of 
approach could be establish  as a means to discover novel host protein candidates 
that could possibly be earmarked for future development of anti-viral therapies.  
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3. MATERIALS AND METHODS 
 
3.1 CELL CULTURE 
 
Human hepatoma (HuH-7) cells (ATCC) and Baby Hamster Kidney (BHK-21) cells 
(ATCC) were maintained in Dulbecco's Modified Eagle's Media (DMEM) (Sigma-
Aldrich) and RPMI-1640 (Sigma-Aldrich), respectively. Both media were 
supplemented with 10% Fetal Calf Serum (FCS) (HyClone). Upon reaching 80% 
growth confluency, the cell monolayer was rinsed with phosphate-buffered saline 
(PBS) to remove dead cell and debris before addition of 1X trypsin-EDTA. Once the 
HuH-7 or BHK-21 cells have detached from the bottom of the flask, fresh DMEM or 
RPMI-1640 was added to stop the reaction of trypsin. The cells were then passaged 
at a ratio of 1:10 into new T75 tissue culture flasks (Iwaki) and maintained at 37oC 
with 5% CO2. Aedes albopictus (C6/36) cells were grown in L-15 (Leibovitz) Media 
(Sigma-Aldrich) supplemented with 10% heat inactivated FCS at 28°C, with normal 
atmospheric CO2 concentration. C6/36 cells were passaged at a ratio of 1:3 upon 
reaching growth confluence.  
 
3.2 VIRUS PROPAGATION 
 
Dengue virus serotype 2 (DENV2), strain New Guinea C (NGC) used in this study 
was propagated in C6/36 cells. Upon reaching approximately 80% growth 
confluency, C6/36 cells were inoculated with 1 mL of DENV2 (NGC) with a virus titer 
of 6 x 106 PFU/mL. After 1 hour incubation at 37oC with rocking every 15 minutes, 10 
mL of L-15 media supplemented with 2% heat inactivated FBS was added to the 
flask. The infected cells were then incubated at 28oC and observed daily for signs of 
cytopathic effect (CPE), characterized by formation of multi-cell syncytia. The 
supernatants containing progeny virus were collected and cleared of cellular debris 
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by centrifugation at 1,500 rpm with Eppendorf Centrifuge 5810R, before being 
aliquoted and stored at -80oC for future use. 
 
3.3 VIRAL PLAQUE ASSAY 
 
BHK-21 cells were plated onto 24-well plates (NUNC™) at a cell density of 7.5 x 104 
cells per well. The following day, the media was aspirated and 100µL of 10-fold serial 
dilutions of viral supernatant was added to the BHK-21 monolayer for one hour at 
37°C with rocking at every 15 minute interval. Following adsorption of virus, the cell 
monolayer was subjected to a single washing step with 1X PBS before adding 1mL 
of overlay media comprising RPMI-1640 with 1% carboxymethylcellulose 
(CMC/Aquacide II, Calbiochem) supplemented with 2% FCS. The assay plates were 
allowed to incubate at 37oC for 4-5 days. At the end of the incubation, the overlay 
media was removed, washed and the cells were fixed and stained simultaneously 
with a staining solution containing 4% paraformaldehyde (Sigma-Aldrich) and 1% 
crystal violet (Sigma-Aldrich) for minimum of four hours. Once stained, the staining 
solution was removed and the stained cell monolayer allowed to dry. Since viral 
plaque formation within the cell monolayer is formed by cell lysis due to localize 
infection of viruses, the counting of viral plaques (in triplicate) would provide an 
estimation of the virus titer of the supernatant expressed as plaque forming units per 
milliliter (PFU/mL). 
 
3.4 SMARTPOOL SIRNA 
 
All the siRNAs used to silence clathrin, vimentin, hypoxia-inducible factor 1 alpha 
subunit (HIF1α), endothelial PAS domain-containing protein 1 (EPAS1), as well as 
aryl hydrocarbon receptor nuclear translocator (ARNT) were acquired from 
Dharmacon. To ensure maximum knock-down with minimum toxicity and off-target 
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effects, each of the gene’s transcript is targeted by a SMARTpool of four siGENOME 
siRNAs (Dharmacon’s own proprietary SMARTselection algorithm). 
 
3.5 TRANSFECTION OF SIRNA 
 
Transfection of siRNA into HuH-7 cells was based on a serum starvation protocol 
using DharmaFECT®4 (Dharmacon) in either the 24-well or the 384-well microtiter 
plate. To ensure that the concentration of DharmaFECT®4 used for delivery of siRNA 
achieved maximal delivery and minimal cytotoxicity, optimization was carried out. 
Cytotoxicity of DharmaFECT®4 was determined by the use of cell viability assay 
(refer to 3.6 Cell Viability Assay) on varying concentrations of DharmaFECT®4 
whereas optimal concentration of DharmaFECT®4 was determined using siGLO® 
Green (Dharmacon) transfection indicator. The siGLO® Green is a specially modified, 
fluorescent RNA duplex, used as a qualitative indicator of successful transfection. 
 
For the transfection of siRNA, culture media in individual wells seeded with HuH-7 
cells was first replaced with 500µL of OPTI-MEM® reduced serum media (Gibco™). 
After four hours of starvation with OPTI-MEM®, HuH-7 cells were transfected with 
transfection cocktails containing 1.0µL of DharmaFECT®4 in 500uL of OPTI-MEM® 
containing different concentrations of siRNA (0nM to 100nM). The transfection 
cocktails were then added into individual wells and incubated at 37oC with 5% CO2 
for 48 hours before subsequent experiments were carried out. 
 
3.6 CELL VIABILITY ASSAY 
 
Cell viability assay was performed in a 96-well microtiter plate format using the 
alamarBlue® reagent (Invitrogen). 10µL of alamarBlue® reagent was added to every 
100µL of cell culture media in individual wells. The cells were then incubated at 37oC 
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for four hours. After four hours, the plate was measured in a fluorescent microplate 
reader (Infinite® 200, Tecan) for the production of fluorescence at the excitation 
wavelength of 570nm and emission wavelength of 585nm. alamarBlue® is cell 
viability indicator that uses the reducing capability of viable cells to convert resazurin, 
a non-toxic and non-fluorescent cell permeable compound, to the fluorescent 
molecule, resorufin.  Resorufin produces a bright red fluorescence, in proportion to 
the amount of viable cells present, which can be measured quantitatively. 
 
3.7 SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) AND WESTERN BLOT 
 
At 48 hours post-transfection, the HuH-7 cells which were transfected with different 
concentration of siRNA (0nM to 100nM) were lysed with 100µL of CellLytic™ M Cell 
Lysis Reagent (Sigma). Aliquots of 20µL of each cell lysate were electrophoresis and 
resolved with 10% polyacrylamide gel (Table 3.1 for formula in setting up of the gel). 
Western blot was then performed according to standard protocol to transfer the 
separated proteins onto nitrocellulose membrane (Bio-Rad Laboratories). 
Colorimetric detection of proteins was performed using the WesternBreeze® 
Chromogenic Western Blot Immunodetection Kit (Invitrogen) in conjunction with the 
use of mouse anti-clathrin monoclonal antibody (1:500) (Chemicon), mouse anti-
vimentin monoclonal antibody (1:500) (Chemicon) and mouse anti-actin monoclonal 
antibody (1:1000) (MAB1501R, Millipore). 









Table 3.1: Formula of stacking gel (5%) and resolving gel (10%) for SDS-PAGE. 
Component            (All volume in mLs)  
    5mL  10mL  15mL  20mL 
 
5% Stacking Gel 
 
Water (H2O)   3.4  6.8 
30% Acrylamide  0.83  1.7 
1.0M Tris (pH 6.8)  0.63  1.25 
10% SDS   0.05  0.1 
10% Ammonium persulfate 0.05  0.1 
TEMED    0.005  0.01 
 
10% Resolving Gel 
 
Water (H2O)   1.9  4.0  5.9  7.9 
30% Acrylamide  1.7  3.3  5.0  6.7 
1.5M Tris (pH 8.8)  1.3  2.5  3.8  5.0 
10% SDS   0.05  0.1  0.15  0.2 
10% Ammonium persulfate 0.05  0.1  0.15  0.2 
TEMED    0.002  0.004  0.006  0.008 
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The enhanced chemiluminescent (ECL) detection method was used for the detection 
of hypoxia-inducible factor 1 alpha subunit (HIF1α), endothelial PAS domain-
containing protein 1 (EPAS1), also known as HIF2α and aryl hydrocarbon receptor 
nuclear translocator (ARNT), also known as HIF1β. A two-step protocol with 0.5% 
skimmed milk as the blocking agent and Tris-buffered saline Tween-20 (TBS-T) as 
the washing solution was used. The following primary antibodies: mouse anti-HIF1α 
monoclonal antibody (1:1000) (Millipore), mouse anti-EPAS1 monoclonal antibody 
(1:1000) (Millipore) and mouse anti-ARNT monoclonal antibody (1:1000) (Upstate), 
was used in conjunction with ImmunoPure® peroxidase-conjugated goat anti-mouse 
IgG (H+L) antibody (1:2500) (Thermo Scientific). All antibodies were allowed to 
incubate with the membrane for one hour at room temperature. The membrance was 
washed thrice after the incudation of antibodies. Lastly, the SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo-Scientific) was added to produce 
luminescence that creates an image of the protein band when placed against CL-
XPosure™ clear blue X-ray film (Thermo Scientific). 
 
3.8 SIARRAY™ PROTEIN HYDROXYLASE SIRNA LIBRARY 
 
The siARRAY™ protein hydroxylases siRNA library used for the siRNA screen was 
acquired from Dharmacon. The siRNA library was available in a 96-well format and 
comprised of validated siRNAs targeting 24 human protein hydroxylases, which 
catalyses the hydroxylation of lysine, proline and aspargine on protein substrates 
essential for cellular biosynthesis. Similar to the the SMARTpool siRNA, each 
protein’s transcript was targeted by a SMARTpool of four siGENOME siRNAs. Each 
siARRAY™ siRNA library contained built-in controls: siCONTROL Non-targeting 
siRNA pool, siCONTROL RISC-free siRNA, siCONTROL siGLO RISC-free siRNA, 
GADPH SMARTpool siRNA, siCONTROL CycloB Duplex and siCONTROL Lamin 
A/C, to ensure validity of the screening results. 
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3.9 384-WELL HIGH THROUGHPUT SIRNA SCREENING ASSAY 
 
The 384-well siRNA high throughput screening (384-siRNA-HTS) assay was adapted 
from the forward transfection protocol and utilized immunofluorescence assay as the 
primary assay to evaluate the results of the siRNA screening assay (Figure 3.1) 
(refer to 3.5 Transfection of siRNA and 3.10 Immunofluorescence Assay). 
 
HuH-7 cells were seeded into each well at a density of 4 x 103 cells. The cells were 
allowed to adhere to the well bottom to form a monolayer by overnight incubation at 
37oC with 5% CO2. The overnight DMEM growth media was then replaced with Opti-
MEM® to allow the HuH-7 cells to starve for four hours. During starvation, the siRNA 
from the 96-well siARRAY™ protein hydroxylase library was rehydrated with a 
transfection cocktail containing DharmaFECT®4 and DharmaFECT Cell Culture 
Reagent (Dharmacon) at a ratio of 1:500. After starvation, the rehydrated siRNA was 
transferred into the 384-well microtiter in triplicates. Hence, each well of the 384-well 
microtiter plate would contain 40nM of SMARTpool siRNA targeting the transcript of 
one protein hydroxylase. The 384-well microtiter plate was then incubated at 37oC 
with 5% CO2 for 48 hours for gene silencing to take place. 
 
After 48 hours, the transfected HuH-7 cells were infected with DENV2 (NGC) with the 
multiplicity of infection (MOI) of 10. The cells were overlaid with DENV2 (NGC) 
diluted with DMEM for one hour at 37oC. After adsorption of the virus, the HuH-7 
cells were washed twice with PBS before replacing with DMEM containing 2% FCS.  










Figure 3.1: The 384-well high-throughput siRNA screening assay. The work flow of the 384-
well high-throughput siRNA screening assay begins with the seeding of cells into the 384-well 
microtiter plate prior to transfection of siRNAs targeting a specific gene per well. Infection of 
cells with virus was carried out post-transfection before evaluation of the screening assay with 
immunofluorescence assay. 
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The virus infected cells were allowed to incubate for another three days at 37oC with 
5% CO2 to allow for virus replication to take place before being fixed and evaluated 
by immunofluorescence assay. 
 
3.10 IMMUNOFLUORESCENCE ASSAY 
 
Immunofluorescence assay (IFA) made use of the specificity of antibodies to “label” 
the protein of interest with a fluorophore so that it could be observed under a 
fluorescence microscope. For the purpose of developing the HTS platform, IFA was 
used as the assay to detect for DENV2 replication in HuH-7 cells by staining for the 
presence of DENV2 viral protein in the cytoplasm of the infected cells. 
 
Before the assay could be carried out, cells must first be fixed with ice cold absolute 
methanol (Merck) for 15 minutes at 4oC. Fixation not only allowed for the cells to 
adhere to the surface but also made the cell membrane semi-permeable to allow 
antibodies to penetrate the cells. The fixed cells were then rehydrated by replacing 
the methanol with PBS for 30 minutes at room temperature (RT). That was followed 
with the addition of a blocking solution of PBS containing 1% bovine serum albumin 
(BSA) at 37oC for one hour. The blocking solution will prevent non-specific binding of 
antibodies in subsequent steps of the IFA. After the blocking step, the cells were 
washed thrice by rinsing with PBS before addition of the primary (1o) antibody 
solution. The 1o antibody solution containing a 1:500 dilution of mouse anti-dengue 
type 2 monoclonal antibodies (United States Biologicals) was added to the cells and 
allowed to incubate at 37oC for 1 hour. After one hour of incubation, the cells were 
washed thrice by rinsing with PBS prior to the addition of the secondary (2o) antibody 
solution. The 2o antibody solution contained a 1:1000 dilution of goat anti-mouse IgG 
secondary antibody conjugated with FITC (Chemicon International) and was 
incubated with the cells for one hour at 37oC. After the 2o antibody incubation, the 
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cells were washed thrice by rinsing with PBS. Lastly, 4',6-diamidino-2-phenylindole 
(DAPI) a fluorophore that binds strongly to DNA was added to the cells at a 
concentration of 300nM to stain for the cell nucleus. After the final wash by rinsing 
the cells thrice with PBS, the wells were then filled with PBS, sealed and imaged on 
the Image Xpress (Molecular Devices). 
 




Using ImageXpress Micro™ (Molecular Devices), an automated microscope image 
acquisition system, nine fields per well were randomly selected for image capture of 
the DAPI and FITC channels. Parameters for autofocus and image collection were 
preset by the software, MetaXpress® (MetaMorph). The captured images were then 
analyzed by the cell count algorithm found within the MetaXpress®. The cell scoring 
algorithm essentially detected and scored fluorescent emission of two different 
wavelengths (DAPI-nucleus and FITC-cytoplasm). Subsequently, the results of the 
cell count were presented as average number of cells per field and percentage of 
DENV2-infected cells per field (Figure 3.2). Silenced hydroxylases which showed 
more than 40% difference (p-value < 0.0125) when normalized to the positive control 
were regarded as “hits” for the screening experiment. 
 
3.12 SECONDARY ASSAY 
 
“Hits” from the siRNA screening assay were further confirmed by the use of the 
chemicals Cobalt(II) chloride hexahydrate [Co(II)Cl2] (Sigma-Aldrich) and Iron(II) 
chloride tetrahydrate [Fe(II)Cl2] (Sigma-Aldrich). Both chemicals function as chelating 
agents to remove O2 from the growth media when added and have been used 
extensively in the study of hypoxia inducible pathway [Jaakkola et al., 2001; Piret et 
al., 2002]. 







Figure 3.2: ImageXpress Micro
™
 automated acquisition and analysis system by Molecular 
Devices, is an imaging system with fully-integrated hardware and software system for 
automated acquisition and analysis of images for high throughput cell-based screening. A) 
Fluorescence images of different fields within individual wells are acquired automatically once 
the desired fluorescence wavelength (DAPI and FITC) and the autofocus parameters were 
input into the system. The captured images are subsequently analyzed by MetaXpress
®
, built-
in cellular image analysis software for high content screening assays which enables users to 
perform an array of different image analysis. B) Total cell count is derived from counting the 
total number of detected DAPI signals. The number of viral infected cells was expressed as a 
percentage of viral infection, derived from detection of FITC signals at the peri-nuclear region 
of the infected cells. 
A 
B 
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Before the secondary assays could be carried out, the effective concentration range 
of both Co(II)Cl2 and Fe(II)Cl2 (0nM to 300nM) were verified to be non-toxic to HuH-7 
cells by alamarBlue® cell viability assay. 
 
HuH-7 cells were exposed to different concentrations of Co(II)Cl2 and Fe(II)Cl2 for 24 
hours before infection with DENV2 (NGC) at MOI of 1. The infected cells were then 
incubated at 37oC with 5% CO2 for another 72 hours before harvesting the infection 
media to determine the virus titer by viral plaque assay. The experimental timeline is 
as shown in Figure. 3.3A. 
 
The drug, Chetomin (Calbiochem) extracted from Chaetomium sp. was also used in 
the secondary assays. Chetomin is a cell-permeable antimicrobial that disrupts the 
CH1 domain structure of p300, hence preventing the association of p300 with CH1-
interacting proteins, such as HIF-1α [Kung et al., 2004]. Since chetomin is only 
soluble in Dimethyl sulfoxide (DMSO), the effective concentration range (0nM to 
300nM) as well as a solvent control (0.1% DMSO) was subjected to cellular toxicity 
testing with alamarBlue® cell proliferative assay prior to the assay proper. 
 
HuH-7 cells were exposed to different concentrations of chetomin (0nM to 300nM), 
either or both Co(II)Cl2 and Fe(II)Cl2 (0nM to 300nM), 24 hours prior to infection with 
DENV2 (NGC) at MOI of 1. The infected cells were then incubated at 37oC with 5% 
CO2 for a maximum of 72 hours with daily replacement of infection media containing 
chetomin, either or both Co(II)Cl2 and Fe(II)Cl2 to ensure for accurate concentrations 
of chetomin throughout the duration of infection. The DENV2 virus titer of the infected 
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‘Hits’ from the siRNA screening assay were further verified with the use of siRNA-
mediated gene silencing against HIF1α, HIF2α/EPAS1 and / or HIF1β/ARNT in HuH-
7 cells. HuH-7 cells were transfected with increasing concentrations (0nM to 100nM) 
of HIF1α, HIF2α and/or HIF1β siRNA for 48 hrs before infection with DENV2 (NGC) 
at MOI of 1. The infected cells were then incubated at 37oC with 5% CO2
 for another 
72 hours before harvesting the infection media to determine the virus titer by plaque 
assay. To ensure that the level of protein knock-down remains significant at 72 hrs 
post-infection, protein expression levels of HIF1α and HIF 1β in HuH-7 cells were 
determined at the time of harvest of viral supernatant. The experimental timeline is as 
shown in Figure. 3.3B.       
 
 
3.13 TOTAL CELLULAR RNA EXTRACTION 
 
Extraction of total RNA was carried out using the Total RNA Mini Kit (Geneaid). The 
kit is based on the selective binding properties of RNA to a silica-gel based 
membrane coupled with the microspin column technology to extract RNA from the 
cell lysate. The cells were first lysed with a lysis RB buffer which contained RNase 
inhibitors. The released RNA will then be bound to the membrane at the base of the 
spin column. The efficiency of the binding was further enhanced by the presence of 
carrier RNA, buffering conditions and the addition of ethanol. To remove any 
contaminating DNA, proteins and lipids, the bounded RNA was washed twice with 
W1 buffer and Wash buffers before incubating with 30 Kunitz units of RNase-Free 
DNase (QIAGEN) per spin column. Finally, the RNA was eluted with 50µL of RNase-
free H2O. The concentration of the RNA was measured at 260nm with the 
NanoDrop® ND-1000 UV-Vis Spectrophotometer. 
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3.14 REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION 
POLYMERASE CHAIN REACTION 
 
Detection of gene transcript copy numbers was carried out with the Real-time 
quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) using the 
SYBR® Green Quantitative RT-PCR Kit (Sigma Aldrich) and its recommended 
thermal cycling profile on the Applied Biosystems™ ABI PRISM 7000 Sequence 
Detection System. The recommended thermal cycling profile is as follows: 
 
Step     Temperature  Duration Cycles 
 
Reverse Transcription        44
o
C    30 min      1 
RT Inactivation             94
o
C      2 min      1 
Denaturation         94
o
C    15 sec      40* 
Annealing & Extension        60
o
C      1 min     40* 
 
* Denaturation step was immediately followed by the annealing and extension step (1 
complete cycle), and the coupled cycle was repeated for a total of 40 cycles.  
 
The kit contained enzymes which allowed the complete real-time qRT-PCR reaction 
to be performed within a single reaction tube. Firstly, the mRNA was reverse 
transcribed into cDNA by the Murine Leukemia Virus Reverse Transcriptase (MLV-
RT). The cDNA was then used as the starting template for subsequent DNA 
amplifications. A 50µL reaction mix would have a final concentration of 250nM of 
primers (Table 3.2) and 10ng of RNA contained in the following reaction formula: 
 
Reagent         Quantity 
 
2X SYBR Green Taq Ready Mix       25.00 µL 
ROX Reference Dye          0.50 µL 
Forward Primer [5 µM]          2.50 µL 
Reverse Primer [5 µM]          2.50 µL 
MLV RT           0.25 µL 
RNA Template         10.00 µL 
RNase free H20           9.25 µL 
 
Final Reaction Volume       50.00 µL 
 






 PCR ARRAY SYSTEM 
 
The gene expression profile of the NFκB transcription factor was analyzed using the 
RT2 Profiler™ PCR Array System (SABioscience™). Using the PCR array system, the 
expression profile of 84 key genes related to the NFκB signal transduction pathway 
was analyzed via a two-step protocol. 
 
Firstly, the total RNA extracted from DENV2-infected HuH-7 cells in the state of 
cellular hypoxia, induced by Co(II)Cl2 and Fe(II)Cl2 as well as the control (normal 
atmospheric O2 concentration) were subjected to reverse transcription into cDNA 
with the RT2 First Strand Kit (SABioscience™) according to the recommended thermal 
cycling profile with the following reaction formula: 
 
Step: First Strand Synthesis  Temperature  Duration Cycles 
 
Reverse Transcription        42
o
C      5 min      1 
RT Inactivation              4
o
C       1 min      1 
 
 
Reagent         Quantity 
 
Total RNA           8.00 µL 
Genomic DNA Elimination Mix         2.00 µL 
5X RT Buffer           4.00 µL 
Primer and Control Mix          1.00 µL 
RT Enzyme Mix           2.00 µL 
RNase free H20           3.00 µL 
 
Final Reaction Volume       20.00 µL 
 
The cDNA was subsequently used to prepare an experimental cocktail mix. Next, 
25µL of the cocktail was then transferred into the individual well of the 96-well plate 
of the PCR array, and the recommended thermal cycling profile was run on the 
Applied Biosystems™ ABI PRISM 7000 Sequence Detection System. The thermal 
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cycling profile and formula for preparation of the experimental cocktail for one PCR 
array was as follows: 
 
Step: Real-time PCR   Temperature  Duration Cycles 
 
Taq Polymerase Hot Start       95
o
C    10 min      1 
Denaturation         95
o
C    15 sec      45* 
Annealing & Extension        60
o
C      1 min     45* 
 
* Denaturation step was immediately followed by the annealing and extension step (1 
complete cycle), and the coupled cycle was repeated for a total of 45 cycles.  
 




 qPCR Master Mix       1350.00 µL 
First Strand cDNA Reaction             8.27 µL 
5X RT Buffer         1341.73 µL 
 
Final Cocktail Volume        2700.00 µL 











Table 3.2: Nucleotide sequences of real-time qRT-PCR primers [White et al., 2004]. 
Gene  Direction Nucleotide Sequence    Tm 
 
HIF1α  Forward 5’-AGTGCCACATCATCACCATATAGAGAT-3’ 66
o
C 
  Reverse 5’-CTGTTCTATGACTCCTTTTCCTGCT-3’ 65oC 
 
EPAS1  Forward 5’-CAGTGCTACGCCACCGAGTA-3’  66
o
C 
  Reverse 5’-CTTGCCATGCCTGACACCT-3’  66oC 
 
β-Actin  Forward 5’-AGCGCGGCTACAGCTTCA-3’   67
o
C 
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4. DEVELOPMENT OF 384-WELL SIRNA SCREENING ASSAY 
 
In order to develop the 348-well high-throughput siRNA screening assay, several 
parameters such as optimal seeding cell density, optimal concentration of 
transfection agent to be used, the time point to process the screening assay for 
visualization via immunofluorescence assay as well as the various controls for the 
assay was determined in this study. Subsequently these parameters would be 
validated by calculation of the Z-factor before the actual screening assay could be 
conducted. 
 
4.1 DETERMINATION OF OPTIMAL SEEDING CELL DENSITY 
 
The optimal density of cells seeded into each of the 384-well plate has to be 
determined. The most important consideration to note in determining the optimal cell 
density is the duration of the whole screening assay before the final acquisition of 
screening data. Cells which have been seeded into individual wells will continue to 
grow and divide. Hence, an initial cell density which was too dense will result in the 
overlapping of cells which will make cell counting impossible. In contrast, a cell 
density which was too sparse will result in too few cells and cause cells lifting off 
during the washing step of the immunofluorescence assay protocol, hence resulting 
in a cell count which was not significant. 
 
In order to determine the optimal cell density, individual wells of the 384-well plate 
were seeded with different densities of HuH-7 cells (3,000 cells/well to 6,000 
cells/well), allowed to grow overnight before being fixed and stained with DAPI for 
cell density visualization. From the fluorescence micrograph (Figure 4.1), the optimal 
cell seeding density was set at 4000 HuH-7 cells per 384-well. 









Figure 4.1: Fluorescence image of HuH-7 cells with nuclei stained with DAPI. HuH-7 cells 
were seeded into individual well of the 384-well plate at varying cell densities of A) 3,000 cells 
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4000 HuH-7 cells per well was deemed as optimal because it provided a reliable 
count on the number of cells per well after immunofluorescence assay yet did not 
result in cells lifting during the washing procedure.  
 
4.2 OPTIMIZATION OF DHARMAFECT
®
4 CONCENTRATION FOR 
EFFICIENT SIRNA TRANSFECTION 
 
The next parameter which required optimization was the concentration of 
DharmaFECT®4 used for the delivery of the siRNAs into the HuH-7 cells. Since 
DharmaFECT®4 is a cationic-lipid-based delivery vector; the use of too high a 
concentration would induce toxicity and could result in cell death. Hence, HuH-7 cells 
were exposed to different concentrations of DharmaFECT®4 (1.6 ug/mL to 2.6 
ug/mL) for 48 hours prior to alamarBlue® cell viability assay to determine for 
cytotoxicity. Exposing the HuH-7 cells to siRNA for 48 hours was within the 
recommended time for efficient siRNA transfection to induce adequate knock-down 
of target genes (according to manufacturer’s instructions). This would ensure that 
HuH-7 cells were tolerable not only to the concentration but also to the time of 
exposure to DharmaFECT®4. The readings of the alamarBlue® cell viability assay of 
HuH-7 cells which were exposed to DharmaFECT®4 was compared to an 
experimental control of HuH-7 cells not exposed to DharmaFECT®4, deemed with a 
cell viability of 100 percent. The alamarBlue® cell viability assay showed that the 
HuH-7 cells could tolerate up to 2.6 µg/mL of DharmaFECT®4 with minimal cell death 
(> 92% cell survivability), and the concentration of 2.0 µg/mL displayed the least cell 
death when compared to HuH-7 cells which were not exposed to any 
DharmaFECT®4 (Figure 4.2). 
 
Although the optimal concentration of DharmaFECT®4 was determined to be non-
toxic to the HuH-7 cells, it was not yet determined whether the concentration of 
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DharmaFECT®4 was sufficient to deliver siRNAs efficiently into the HuH-7 cells. 
Hence, a range of concentration (0 nM to 100 nM) of siRNA targeting an abundant 
protein which was not essential for cell survival would have to be transfected to 
determine the transfection efficiency of DharmaFECT®4. 
 
The efficiency of 2.0 µg/mL of DharmaFECT®4 was in delivering siRNA into HuH-7 
cells was assessed using clathrin as the target gene. After 48 hours post-transfection 
with clathrin-siRNA, the transfected HuH-7 cells were fixed and stained for clathrin 
using IFA. From the fluorescence micrograph (Figure 4.3), it was shown that 2.0 
µg/mL of DharmaFECT®4 efficiently delivered up to 100nM of clathrin-siRNA into 
HuH-7 cells. It was also observed that rhodamine fluorescence signal, which was 
tagged to antibody targeting clathrin, showed signs of signal depletion with 30nM of 
clathrin-siRNA and almost no signal detected from 50nM onwards, hence indicating 
the efficient dosage dependent knock-down of clathrin. 
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Figure 4.2: Cell viability assay of HuH-7 cells. HuH-7 cells were exposed to different amounts 
of DharmaFECT
®
4 for 48 hours. The cytotoxicity of DharmaFECT
®
4 was subsequently 
determined by the use of alamarBlue
®
 cell viability assay. Readings of the alamarBlue
®
 cell 
viability assay were normalized against a blank control which contained only growth media 
without any HuH-7 cells before comparison with a normal control of similar density HuH-7 
cells not treated with DharmaFECT
®
4. 
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4.3 DETERMINATION OF OPTIMAL TIME POINT FOR VISUALIZATION OF 
DENV2-INFECTED HUH-7 CELLS VIA IMMUNOFLUORESCENCE ASSAY 
 
The optimal time point for visualization of DENV2 infected HuH-7 cells via IFA was 
another parameter to be determined. If the DENV2-infected HuH-7 cells were fixed 
too early in the replication cycle, it would result in low signal detection of DENV2 viral 
protein by IFA. If the DENV2-infected HuH-7 cells were fixed too late in the later 
stages of the replication cycle, the DENV2 detection signal would be too 
overwhelming and significant cell death would also have occurred, hence making the 
visualization of DENV2 viral protein signal difficult. In summary, HuH-7 cells were 
fixed at different time-points after infection by DENV2 at MOI of 1, and stained with 
antibodies tagged with FITC targeting DENV2 viral protein. Results of the IFA were 
also correlated with the virus titer obtained from the growth media harvested from 
DENV2-infected HuH-7 cells at similar time-points. 
 
Results of the IFA showed that HuH-7 cells which were fixed on day 3 post-infection 
displayed the most even distribution of infected and non-infected cells (Figure 4.4).  
 
This was in contrast to Day 1 and 2 post-infection where too few DENV2-infected 
cells were stained by IFA, while Day 4 and 5 post-infection had too many DENV2-
infected cells which complicated the cell counting algorithm. The IFA results 
observed correlated with the virus growth curve where the peak of DENV2 release 
from HuH-7 cells was on Day 3 as indicated by viral plaque assay (Figure 4.5). On 













Figure 4.3: Efficient delivery of clathrin-siRNA into HuH-7 cells by DharmaFECT
®
4. HuH-7 
cells were transfected for 48 hours with clathrin-siRNA at different concentrations: A) 0nM B) 
30nM C) 50nM and D) 100nM. Clathrin in HuH-7 cells was stained by monoclonal antibody 
tagged with rhodamine while the cell nucleus was stained with DAPI after 48 hours. The 
intensity of rhodamine fluorescence signal is proportional to the amount of clathrin present 










Figure 4.4: Visualization of DENV2 proteins in HuH-7 cells. HuH-7 cells infected with DENV2 
(NGC) at MOI of 1 were fixed at various time-points post-infection, A) Day 1, B) Day 2, C) Day 
3, D) Day 4 and E) Day 5. HuH-7 cell nuclei were stained with DAPI while infected cells were 
indicated by the presence of DENV2 viral protein at the peri-nuclear region, stained with anti-

















































Figure 4.5: Growth curve of DENV2 (NGC) in HuH-7 cells. HuH-7 cells were infected with 
DENV (NGC) at MOI of 1 and the growth curve was derived by determining the DENV2 titer in 
the cell culture media by viral plaque assay, which were harvested from infected HuH-7 cells 
at daily intervals of post-infection. 
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4.4 VIMENTIN WAS SELECTED AS THE POSITIVE CONTROL OF THE 384-
WELL SIRNA SCREENING ASSAY FOR DENV2 INFECTION 
 
Once the basic screening parameters of the siRNA screening assay had been 
determined, the next phase of the assay development was to select for a positive 
control. The positive control would not only be used in the screening assay as an 
experimental control but would also serve as a means of comparing the effectiveness 
of each silenced gene in modulating the replication of DENV2. The gene selected as 
the positive control must certainly reduce the replication of DENV2 when silenced in 
HuH-7 cells. Recent findings from Suksanpaisan et al (2009) and a recent publication 
from the lab [Ang et al., 2010] have indicated that two cellular proteins, clathrin and 
vimentin, respectively, might be involved in the replication of DENV2. It is 
hypothesized that clathrin-mediated endocytosis plays a role in DENV2 by entry into 
host cells [Suksanpaisan et al., 2009] while vimentin possibly acts as a structural 
scaffold for the DENV2 replication complex within the host cells [UROPS Project 
Report of Kuan Ling Li Sabrina, March 2009]. 
 
To investigate whether the clathrin or vimentin gene would be more suitable as the 
positive control, both of these genes were silenced by the validated SMARTpool 
siRNA from Dharmacon to determine the extent of modulation in DENV2 replication. 
Within each SMARTpool siRNA is a cocktail of four validated siRNAs targeting the 
same RNA transcript which encodes for the protein, hence only minute amount of 
each siRNA would be required to achieve maximum gene silencing while keeping off-
target effects to the minimal. Hence, the extent of modulation by clathrin and vimentin 
could be determined by the reduction in virus titer derived from the growth media of 
the siRNA-transfected HuH-7 cells at 72 hrs post-infection.  
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Also, to prove that the reduction in DENV2 virus titer was indeed due to the knock-
down of clathrin and vimentin, Western blot was used to verify that the expression 
levels of respective proteins remain significantly reduced at 72 hrs post-infection. 
 
Clathrin-siRNA was still effective in maintaining low levels of clathrin protein 
expression in HuH-7 cells after 72 hours post-infection (Figure 4.6A). The clathrin-
siRNA was also observed to be highly specific as no knock-down of clathrin was 
observed for HuH-7 cells transfected with the scrambled-siRNA. Analysis of the 
growth media of clathrin-siRNA transfected and DENV2-infected HuH-7 cells 
revealed that the knock-down of clathrin indeed caused a dosage-dependent 
reduction of DENV2 replication in HuH-7 cells (Figure 4.6B). 
 
Similarly, colorimetric detection of vimentin was carried out on Western blot and it 
was observed that vimentin-siRNA was equally if not more effective in the knock-
down of vimentin in HuH-7 cells (Figure 4.7A). Furthermore the viral plaque assay 
showed that 20nM of vimentin-siRNA was able to decrease DENV2 production by 
one log10 (Figure 4.7B). 
 
By comparing the results of the effects of clathrin and vimentin knock-down on 
replication of DENV2 in HuH-7 cells, it was clearly shown that vimentin-siRNA could 
achieve a better knock-down effect of its targeted protein. Clathrin-siRNA which 
required at least 80nM to achieve approximately a log10 decrease in DENV2, 
vimentin-siRNA only required 20nM. Hence, the more specific and effective vimentin-
siRNA was chosen as the positive control for the siRNA screening assay.  
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Figure 4.6: Effects of clathrin knock-down on the replication of DENV2. A) Detection of 
clathrin in HuH-7 cells was achieved by Western blot colorimetric detection method with β-
actin as the loading control. HuH-7 cells were transfected with increasing concentration of 
clathrin-siRNA (0nM to 100nM) with a scrambled-siRNA as a knock-down control. B) 
Detection of DENV2 via plaque assay on the growth media of HuH-7 cells, which were 





































Figure 4.7: Effects of vimentin knock-down on the replication of DENV2. A) Detection of 
vimentin in HuH-7 cells was achieved by Western blot colorimetric detection method with β-
actin as the loading control. HuH-7 cells were transfected with increasing concentration of 
vimentin-siRNA (0nM to 100nM) with a scrambled-siRNA as a knock-down control. B) 
Detection of DENV2 virus via plaque assay was carried out using the growth media of HuH-7 
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 4.5 CONSISTENCY AND ROBUSTNESS OF THE NEWLY-DEVELOPED 
SIRNA SCREENING ASSAY PLATFORM 
 
Once vimentin had been successfully validated as the candidate gene for the positive 
control, the modulation effect of DENV2 replication in HuH-7 cells by vimentin was 
then up-scaled, adapted into the 384-well format and interpreted via IFA using 
ImageXpress Micro™. In total, 54 sets of experimental control were evenly distributed 
throughout the 384-well microtiter plate, with each set comprising of a well for non-
infected HuH-7 cells, a well for HuH-7 cells infected with DENV2 and a well for 
vimentin knocked-down HuH-7 cells infected with DENV2. 
 
The fluorescence image of each individual well was captured and analyzed by the 
built-in cell profiling algorithm of MetaXpress® to derive the average cell count of 
each well and each well’s average DENV2-infected cell percentile (refer to 3.11 
Imaging and Data Analysis by ImageXpress Micro™). The results were then compiled 
to calculate the overall average cell count (n1), overall DENV2-infected HuH-7 
percentile (p1 or n2) and overall DENV2-infected percentile with vimentin knocked-
down (p2). Using the Z Factor formula, two values, Z1 (non-infected vs infected) and 
Z2 (non-transfected vs transfected) was calculated to interpret the robustness and 
consistence of the developed siRNA screening assay across the entire 384-well 
microtiter plate (Table 1.1). 
 
Based on the table from Zhang et a (1999), the developed siRNA screening assay 
was interpreted as an excellent screening assay with Z factors of 0.9325 and 0.8873, 
respectively (Table 4.1). Hence, with a robust assay at hand, we proceeded to 
screen for the effects of human protein hydroxylases on DENV2 replication in HuH-7 
cells. 

















(p1 or n2) 
Knocked-down Infection 
(p2) 
Mean (µ) 0.1521% 60.0251% 14.9609% 
Std Dev (ơ) 0.3708% 0.9762% 0.7173% 
Z Factor (Z) 0.9325 (n1,p1) 0.8873 (n2,p2) 
 
 
Chapter 5: siRNA Screening of Human Protein Hydroxylase 
 55 
 
5. SIRNA SCREENING OF HUMAN PROTEIN HYDROXYLASE 
 
With the successful development of the 384-well based siRNA screening platform, 
we proceeded to screen a small siRNA library of genes as an assessment of the 
assay. The screening of a small siRNA library comprising 24 human protein 
hydroxylases was carried out to determine whether any of the human protein 
hydroxylases could have a role in the replication of DENV2. 
 
5.1 HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT INHIBITOR 
MODULATES DENV2 REPLICATION IN HUH-7 CELLS 
 
The pilot screen of 24 human protein hydroxylases was done in triplicates within a 
single 384-well microtiter plate along with the built-in experimental controls which 
comprised of: non-targeting control, RISC-free control, siGLO control, GADPH 
control, Cyclo B control and Lamin A/C control. These built-in controls were 
incorporated into the screening platform to ensure that any modulation of DENV2 
replication observed due to the knock-down of a specific gene was true and 
unbiased. Also present within the 384-well microtiter plate were the positive control of 
DENV2-infected HuH-7 cells which serves as a basis for comparison of results and 
the negative control of non-infected HuH-7 cells which was used to normalize 
presence of background fluorescence. Results of the screening assay showed that 
the screening assay was successful as the experimental controls had no significant 
effects on the replication of DENV2 (Figure 5.1). In total, six hydroxylases 
significantly (< 0.0125) modulated the replication of DENV2 when their expressions 
were knocked-down (Table 5.1). Of the six hydroxylases, hypoxia-inducible 1 factor, 
alpha subunit inhibitor (HIF1AN) downregulated DENV2 replication by more than 
50% (Figure 5.1). 
 






























































































































































































































Figure 5.1: 384-well high-throughput siRNA screening assay of human protein hydroxylases 
on DENV2 in HuH-7 cells. The effects of hydroxylase knocked-down on the replication of 
DENV2 in HuH-7 cells was analyzed by ImageXpress Micro
™
 to reveal the fold difference of 
DENV2 infection in comparison to the built-in experimental controls. The controls were: non-
targeting control, RISC-free control, siGLO control, GAPDH control, cycloB control and lamin 
A/C control, all of which had no effects on the replication of DENV2. (* p-value of < 0.0125 
when rounded off to nearest 4
th
 decimal, refer to Table 5.1)  





Table 5.1: 384-well high-throughput siRNA screening assay of human protein hydroxylases 
on DENV2 replication in HuH-7 cells. *p-value of < 0.0125 rounded off to nearest 4th decimal. 
Gene Abb Gene Name Infection Std Dev p-value 
HIF1AN* hypoxia-inducible factor 1, alpha subunit inhibitor 47.53% 3.07% 0.0000 
LEPRE1* leucine proline-enriched proteoglycan (leprecan) 1 70.76% 2.37% 0.0000 
LEPREL1 leprecan-like 1  112.05% 8.31% 0.0088 
FLJ22222 hypothetical protein FLJ22222 107.90% 33.80% 0.3536 
EGLN3 egl nine homolog 3 109.23% 22.43% 0.1668 
P4HA1* procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase) 137.66% 23.50% 0.0000 
EGLN1 egl nine homolog 1 95.03% 0.45% 0.2652 
EGLN2 egl nine homolog 2 96.84% 3.05% 0.4777 
FLJ13491 2-oxoglutarate and iron-dependent oxygenase domain containing 2 (OGFOD2) 108.16% 8.43% 0.0604 
FLJ20308 alkB, alkylation repair homolog 5 (ALKBH5) 129.84% 12.44% 0.0000 
FLJ20013 alkB, alkylation repair homolog 4 (ALKBH4) 92.08% 5.82% 0.0518 
ALKBH alkB, alkylation repair homolog 1 90.53% 1.28% 0.0443 
PLOD procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 112.15% 9.90% 0.0228 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2  116.53% 15.70% 0.0056 
PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 118.83% 5.10% 0.0001 
HSPBAP1 HSPB (heat shock 27kDa) associated protein 1 121.08% 11.33% 0.0007 
DEPC-1 alkB, alkylation repair homolog 3 (ALKBH3) 101.93% 0.78% 0.6598 
PHF8 PHD finger protein 8 101.89% 2.50% 0.5995 
JMJD2A jumonji domain containing 2A 96.29% 32.45% 0.6497 
JMJD2C* jumonji domain containing 2C 134.22% 17.99% 0.0000 
ASPH* aspartate beta-hydroxylase 71.33% 17.25% 0.0002 
PTDSR Phosphatidylserine receptor 107.06% 1.62% 0.1221 
FLJ10826 2-oxoglutarate and iron-dependent oxygenase domain containing 1 (OGFOD1) 95.75% 10.13% 0.3875 
JMJD2B* jumonji domain containing 2B 135.55% 1.94% 0.0000 
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A search in the literature revealed that HIF1AN is an inhibitor which acts on the alpha 
subunit of a transcription factor known as hypoxia-inducible factor 1 (HIF1α) [Marx, 
2004]. HIF1α exists in the cytoplasm and requires its beta subunit HIF1β, also known 
as aryl hydrocarbon receptor nuclear translocator (ARNT), a nuclear translocator to 
bring it into the nucleus to carry out its function [Marx, 2004]. In a state of cellular 
hypoxia (low oxygen), both HIF1α and HIF1β work in unison to result in transcription 
and activation of other downstream pathways (Figure 5.2). A literature search on the 
other hydroxylases in our screen reduced DENV2 replication revealed that leucine 
proline-enriched proteoglycan (leprecan) 1 (LEPRE1) and aspartate beta-
hydroxylase (ASPH) also had roles to play in the regulation of HIF1α levels within the 
cell. 
 
5.2 STATE OF CELLULAR HYPOXIA MODULATES REPLICATION OF 
DENV2 IN HUH-7 CELLS 
 
Since the above findings suggested that cellular hypoxia could reduce replication of 
DENV2, HuH-7 cells were subjected to the state of cellular hypoxia by chemical 
means to confirm these initial findings. Cobalt(II) chloride hexahydrate [Co(II)Cl2] and 
iron(II) chloride tetrahydrate [Fe(II)Cl2] function as chelating agents that bind to 
oxygen molecules and convert into the oxidized (III) form, hence inducing the state of 
hypoxia [Jaakkola et al., 2001; Piret et al., 2002]. 
 
Cell viability assay conducted on both HuH-7 cells exposed to Co(II)Cl2 and Fe(II)Cl2 
showed that HuH-7 cells could tolerate up to 300µM of either chemical without 
displaying signs of cellular toxicity (Figure 5.3).  









Figure 5.2: The translocation of hypoxia-inducible factors into the cell nucleus. Both HIF1α 
and HIF2α utilize the aryl hydrocarbon receptor nuclear translocator protein HIF1β to enter 
the nucleus in order to carry out activation of genes from hypoxia-inducible pathway with the 
co-activator p300. 
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 cell viability assay of HuH-7 cells treated with Co(II)Cl2 and Fe(II)Cl2. 
HuH-7 cells were treated with increasing concentrations of A) Co(II)Cl2 and B) Fe(II)Cl2 for a 
total of 96 hours (to mimic treatment 24 pre-infection and 72 hours post-infection) before 
being subjected to alamarBlue
®
 cell viability assay. 
A 
B 
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Hence, HuH-7 cells were exposed to increasing concentrations of Co(II)Cl2 and 
Fe(II)Cl2 (0µM to 300µM) to determine the effects of cellular hypoxia on DENV2 
replication. 
 
Quantification of the virus titer by viral plaque assay revealed that treatment of HuH-7 
cells with Co(II)Cl2 and Fe(II)Cl2 induced a dosage-dependent reduction in the 
replication of DENV2 in HuH-7 cells (Figure 5.4A and 5.4B). 50µM of either chemical 
was sufficient to reduce DENV2 titres 1000 fold. A combination of both Co(II)Cl2 and 
Fe(II)Cl2 did not synergise to further reduce DENV2 replication in HuH-7 cells (Figure 
5.4C). 
 
We wanted to use a more specific inhibitor of the hypoxia-inducible pathway to 
substantiate the results that we obtained with Co(II)Cl2 and Fe(II)Cl2. Chetomin, a 
member of the epidithiodiketopiperazine (ETP) family of natural products isolated 
from Chaetomium species had been identified by Kung et al (2004) as a small 
molecule which blocks the HIF pathway. Chetomin accomplishes this by disrupting 
the structure of the CH1 domain of p300, a transcriptional co-activator of hypoxia-
inducible factors, thereby precluding its interaction with HIF and inhibiting hypoxia-
inducible factor transcription as a result. We wanted to determine whether chetomin 
would enhance DENV2 replication in HuH-7 cells.  
 
Since chetomin is known to exhibit toxicity to cells at high concentrations, a cell 
viability assay for the working concentrations used in this study was carried out prior 
to the infection by DENV2. 
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Figure 5.4: Effects of Co(II)Cl2 and Fe(II)Cl2 on replication of DENV2. HuH-7 cells were 
treated with increasing concentrations (0µM to 300µM) of A) Co(II)Cl2, B) Fe(II)Cl2, and C) 
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Minimal cellular toxicity was noted when HuH-7 cells were treated with up to 300nM 
of chetomin (Figure 5.5). To ensure the optimal efficacy of chetomin on these 
experiments, various concentrations of chetomin (0nM, 150nM, and 300nM) were 
kept optimal by replacing the cell culture media on a daily basis. The viral plaque 
assays of daily cell culture media (day 0 to day 3 post-infection) revealed a dosage-
dependent enhancement of DENV2 replication (Figure 5.6A). In the span of 72 
hours, almost 100-fold (2-log10) enhancement of DENV2 replication was observed in 
HuH-7 cells treated with 300nM of chetomin (Figure 5.6B). These data suggested 
that activation of the hypoxia-inducible pathway did inhibit DENV2 replication in HuH-
7. 







































 cell viability assay of HuH-7 cells treated with chetomin. HuH-7 cells 
were exposed to increasing concentrations of chetomin for 96 hours before being subjected to 
alamarBlue
®
 cell viability assay. 
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Figure 5.6: Effects of chetomin on the replication of DENV2 in HuH-7 cells. HuH-7 cells were 
treated with increasing concentrations (0nM to 300nM) of chetomin throughout the duration of 
infection by DENV2. A) DENV2 virus titer was monitored daily by harvesting the infected 
media for viral plaque assay. B) The daily virus titer was subsequently complied together to 
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5.3 THE HYPOXIC-INDUCIBLE PATHWAY ACTIVATED VIA HIF2α/HIF1β 
IS PREDOMINANTLY RESPONSIBLE FOR THE MODULATION OF DENV2 
REPLICATION IN HUH-7 CELLS 
 
To further elucidate how cellular hypoxia could modulate the replication of DENV2, 
specific gene silencing by siRNA was employed to induce a loss of function in genes 
known to mediate the cellular response to hypoxia. In total, three candidates: 
hypoxia-inducible factor 1 alpha subunit (HIF1α), endothelial PAS domain-containing 
protein 1 (EPAS1) - also known as HIF2α an isoform of HIF1α, and the common aryl 
hydrocarbon receptor nuclear translocator (ARNT) - also known as HIF1β, were 
selected for knock-down to observe for their effects on DENV2 replication (Figure 
5.2). 
 
Since these transcription factors (HIF1α and HIF2α) and its translocator (HIF1β) 
exists only as a basal level of expression within the cells, the effectiveness of these 
genes knock-down by siRNA could only be assessed by means of enhanced 
chemiluminescent (ECL) detection method on a Western blot for increased 
sensitivity. Results from the Western blot ECL showed that all three proteins 
displayed a dosage-dependent decrease in protein expression levels (Figure 5.7A, 
Figure 5.8A and Figure 5.9A). Off-target effects of the siRNAs were also not 
observed for cells transfected with concentrations as high as 100nM and scrambled 
siRNA sequences of these siRNA at 100nM did not result in depletion of the protein 
expression. 
 
In a concurrent set of experiments, these transfected cells were also subjected to 
infection by DENV2. Quantification of virus titer revealed that the decrease in 
expression of HIF1α did not affect the replication of DENV2 in HuH-7 cells (Figure 
5.7B). In contrast, HuH-7 cells which had HIF1β or HIF2α gene knocked-down 
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showed dosage-dependent enhancement of approximately 1.5-log10 and 2-log10 
respectively, in the replication of DENV2 (Figure 5.8B and Figure 5.9B). 
 
Taken together, only HIF2α and HIF1β gene when singly knocked-down revealed a 
significant dosage-dependent enhancement of DENV2 replication. The published 
literature suggests that HIF1β acts as a common nuclear translocator protein of both 
HIF1α and HIF2α [Kung et al., 2004]. Hence, to further elucidate if the modulation of 
DENV2 replication observed is mediated predominantly via the HIF2α / HIFβ 
pathway, a corresponding double knock-down of either HIF1α and HIF1β or HIF2α 
and HIF1β was carried out. It was observed that in the double knock-down of HIF1α 
and HIF1β, the level of enhancement in the replication of DENV2 was comparable to 
that of when HIF1β alone was silenced. These data reaffirmed the lack of 
involvement of HIF1α, and the significance of HIF1β in the modulation of DENV 
replication. The double knock-down of HIF2α and HIF1β genes yielded a dosage-
dependent enhancement in DENV2 replication of approximately 2-log10 (Figure 5.10), 
which was comparable to that of when HIF2α alone was knocked-down. This data 
strongly suggests that HIF2α does act predominantly. Therefore, it could be 
concluded that activation of the hypoxia-inducible pathway via HIF2α/HIF1β was 
largely responsible for the modulation of DENV2 replication in HuH-7 cells (Figure 
5.11).  
 




































Figure 5.7: Effects of HIF1α knock-down on the replication of DENV2 in HuH-7 cells. A) 
Western Blot (ECL) detection of HIF1α in HuH-7 cells transfected with increasing 
concentration (0nM to 100nM) of HIF1α-siRNA. B) DENV2 titer in growth media of HuH-7 


















































Figure 5.8: Effects of HIF1β/ARNT knock-down on the replication of DENV2 in HuH-7 cells. 
A) Western Blot (ECL) detection of HIF1β in HuH-7 cells transfected with increasing 
concentration (0nM to 100nM) of HIF1β-siRNA. B) DENV2 titer in growth media of HuH-7 


















































Figure 5.9: Effects of HIF2α/EPAS1 knock-down on the replication of DENV2 in HuH-7 cells. 
A) Western Blot (ECL) detection of HIF2α in HuH-7 cells transfected with increasing 
concentration (0nM to 100nM) of HIF2α-siRNA. B) DENV2 titer in growth media of HuH-7 
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Figure 5.10: Effects of a combination knock-down on the replication of DENV2 in HuH-7 cells. 
A) HuH-7 cells transfected with a combination of siRNA targeting HIF1α and HIF1β with 
concentration ranging from 0nM to 100nM. B) HuH-7 cells transfected with a combination of 



















Figure 5.11: A diagrammatic view of how the state of cellular hypoxia limits DENV2 
replication in HuH-7 cells by activation of the hypoxia-inducible pathway 
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6. MODULATION OF DENV2 REPLICATION BY HIFS 
 
We next assessed whether the replication of DENV2 in host cells would result in a 
feedback mechanism, leading to an elevation of HIF expression levels. 
 
6.1 REPLICATION OF DENV2 IN HUH-7 CELLS DOES NOT RESULT IN 
INCREASED HIFS 
 
To determine whether infection of HuH-7 cells by DENV2 would lead to an increase 
in HIFs expression, a one-step real-time qRT-PCR was used to detect the transcripts 
of HIF1α and HIF2α. Analysis of the real-time qRT-PCR results, which were 
normalized to expression of β-actin, showed a slight reduction in transcript levels of 
both HIF1α and HIF2α over the course of infection (Figure 6.1A). However, statistical 
analysis showed that the decrease in HIFs transcript levels had p-values of > 0.025 
and could not be considered as significant (Table 6.1). Furthermore, detection of the 
HIF1α and HIF2α proteins via Western blot after infection by DENV2 also indicated 
that DENV2 replication did not modulate changes to their protein expression levels 
(Figure 6.1B).  Hence, it is evident that infection of HuH-7 cells by DENV2 did not 
induce any changes in the expression of HIFs at both the mRNA and protein levels 
(Figure 6.2).  
 























21.81 1.2336 21.89 1.2639 0.9761 
HIF1α 
20.00 1.4276 19.65 1.4127 1.0105 
0.9933 0.7913 
23.26 1.3156 22.49 1.2985 1.0132 
HIF2α 
(EPAS1) 
29.42 2.0999 27.53 1.9792 1.0610 
1.0371 0.4104 




14.01 1.0000 13.91 1.0000 1.0000 
1.0000 Nil 
20.00 1.1521 20.21 1.1966 0.9628 
HIF1α 
17.65 1.1806 17.77 1.2453 0.9481 
0.9554 0.1164 
19.09 1.0997 18.74 1.1095 0.9911 
HIF2α 
(EPAS1) 
19.21 1.2849 19.16 1.3427 0.9570 
0.9741 0.3921 




14.95 1.0000 14.27 1.0000 1.0000 
1.0000 Nil 
23.71 1.1242 23.68 1.2745 0.8821 
HIF1α 
19.42 1.0374 19.42 1.2393 0.8371 
0.8596 0.0927 
30.07 1.4258 29.94 1.6114 0.8848 
HIF2α 
(EPAS1) 
26.76 1.4295 24.54 1.5660 0.9128 
0.8988 0.0962 
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Figure 6.1: Changes in mRNA and protein expression levels of HIF1α and HIF2α in 
HuH-7 cells when infected with DENV at days 1, 2 and 3 post-infection. A) Real-time 
qRT-PCR of HIF1α and HIF2α mRNA levels in HuH-7 cells infected with DENV2. The 
Ct values of HIF1α and HIF2α were first normalized to the Ct values of β-actin (∆Ct). 
Subsequently, the results of DENV-infected samples were compared to the non-
infected samples (∆∆Ct) for fold-differences in transcript levels of HIF1α and HIF2α. 
B) Western blots detection of HIF1α and HIF2α protein expression levels with β-actin 






























Figure 6.2: A diagrammatic representation of the effect of DENV2 infection on the 
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6.2 HYPOXIA-INDUCIBLE FACTORS COULD POSSIBLY MODULATE 
REPLICATION OF DENV2 BY ACTIVATION OF INTERFERON VIA THE NF-ΚB 
PATHWAY 
 
With the knowledge that DENV2 replication does not lead to an increase in 
expression of HIFs, it would be intriguing to gain insights on how HIFs could 
modulate replication of DENV2.  
 
It was mentioned by Yamamoto and Gaynor (2004) that a point of convergence 
exists between the hypoxia-inducible pathway and the pathway of another 
transcription factor, nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB). This convergence point occurs at the level of the IκB kinases (IKKα, IKKβ 
and IKKγ) which are assembled together to form the IκB kinase (IKK) enzyme 
complex, an important step in the activation of the NF-κB pathway. This was further 
supported by evidence which clearly showed that the NF-κB pathway could be 
activated by hypoxia and that the activation was achieved through the IKK complex 
[Cummins et al., 2006]. 
 
The activation of NF-κB has been widely characterized for its role in the host’s 
response to inflammation and it is likely that the state of hypoxia could modulate 
genes in the NF-κB inflammatory response pathway, hence affecting DENV2 
replication (Figure 6.3). Therefore a PCR array profiler system which encompassed a 
total of 84 genes related to the activation of NF-κB was deployed to gain a clearer 















Figure 6.3: A possible mechanism that hypoxic factors could modulate DENV2 
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In total, three separate sets of PCR array experiments were carried out. The results 
for each set of PCR array were derived by comparison of two different types of 
cellular conditions: normal HuH-7 cells (control) and hypoxic HuH-7 cells (test). The 
cellular state of hypoxia was achieved by addition of 300µM of Co(II)Cl2 and Fe(II)Cl2, 
whereas the control was normal HuH-7 cells exposed to solvents for the hypoxic 
mimics. For both types of cellular conditions, total RNA was extracted from HuH-7 
cells at three days post-infection with DENV2 at the MOI of 10. 
 
Before the results of the PCR array could be interpreted, criteria for the built-in QC 
analysis of the PCR array had to be satisfied. The built-in QC analysis comprised of 
three values which were used to define two different criteria: the quality of the first-
strand synthesis product (cDNA) used for PCR and the presence of DNA 
contamination from the final cDNA sample. The three values were: reverse 
transcriptase control (RTC), positive PCR control (PPC) and genomic DNA 
contamination (GDC). The Ct value of the RTC was obtained by a set of primers that 
detect for templates which were synthesized from the RT2 1st strand kit built-in 
external RNA control (spike-in control). Similarly, the PPC tests the efficiency of the 
of the polymerase chain reaction itself using a pre-dispensed artificial cDNA 
sequence and primers which would amplify that particular sequence within the PPC 
control wells. Hence, the quality of cDNA sample used for PCR could be defined by 
the difference between the Ct averages of RTC and Ct averages of PPC. Too large a 
disparity between RTC and PPC would mean that the quality of cDNA sample was 
poor. The presence of genomic DNA in the sample was achieved by specifically 
detecting for non-transcribed genome DNA. Since SYBR Green will bind to double-
stranded nucleic acid, any DNA contamination will artificially inflate the SYBR Green 
signal, yielding skewed gene expression profiles and false positive signals. Hence, 
an average GDC Ct of > 35 would indicate low level of genomic DNA contamination 
in the samples. 
Chapter 6: Modulation of DENV2 Replication by HIFs 
 80 
 
The results of the built-in QC analysis of the PCR array showed that the criteria for 
both the reverse transcription control (average RTC Ct – average PPC Ct ≤ 5) and 
genomic DNA contamination control (Ct ˃ 35) were satisfied for all three separate 
runs (Table 6.2). 
 
Using the ∆∆Ct comparison method, the result of the NF-κB profile PCR array 
revealed that only nine out of the 84 genes within the profiler had p-values which 
were considered significant (p-value < 0.05). And of the six gene candidates, only 
three had differences in fold regulation which were deemed to be significantly 
different (fold difference > ±5) (Table 6.3): interferon type 1, alpha (IFNα), which had 
increased expression of 37.88 fold with a p-value of 0.0254, interferon type 1, beta 
(IFNβ), which had increased expression of 21.61 fold with a p-value of 0.0432, and 
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKε), 
which had a lesser increased in expression by 6.03 fold with a p-value 0.0376 (Figure 
6.4).




Table 6.2: Quality control for the test sample (hypoxia) and control sample (normoxia) for the 
NF-κB profile PCR array. 
Test Sample: Hypoxic 
PCR Array Catalog Number: PAHS-021 
Control Sample: Normoxic 
1. PCR Array Reproducibility: 
Test Sample 
Well exp1 exp2 exp3 AVG exp(1-10) 
ST DEV exp(1-
10) 
Average Ct (PPC) 17.94 18.17 17.74 17.95 0.21 
ST DEV Ct (PPC) 0.13 0.25 0.50 0.29  --  
Average Ct (RTC) 22.48 22.93 22.41 22.61 0.29 
ST DEV Ct (RTC) 0.13 0.08 0.38 0.20  --  
Control Sample 
Well exp1 exp2 exp3 AVG exp(1-10) 
ST DEV exp(1-
10) 
Average Ct (PPC) 18.05 17.84 18.09 17.99 0.14 
ST DEV Ct (PPC) 0.16 0.27 0.34 0.26  --  
Average Ct (RTC) 23.02 22.68 22.78 22.83 0.17 
ST DEV Ct (RTC) 0.04 0.26 0.46 0.25  --  
2. Reverse Transcription Control (RTC):   
Test Sample   
Well exp1 exp2 exp3   
∆Ct (AVG RTC - AVG PPC) 4.54 4.77 4.67 RTC – Reverse Transcription Control 
RT Efficiency Pass Pass Pass PPC – Positive PCR Control 
Control Sample   
Well exp1 exp2 exp3   
∆Ct (AVG RTC - AVG PPC) 4.97 4.85 4.69 RTC – Reverse Transcription Control 
RT Efficiency Pass Pass Pass PPC – Positive PCR Control 
3. Genomic DNA Contamination (GDC):   
Test Sample   
Well exp1 exp2 exp3   
Ct (GDC) 35.00 35.00 35.00   
Genomic DNA: Pass Pass Pass   
Control Sample   
Well exp1 exp2 exp3   
Ct (GDC) 35.00 35.00 35.00   
Genomic DNA: Pass Pass Pass   
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 PCR Array system on NF-κB. The difference in gene 
expression was derived by using the ∆∆Ct method to reflect a relative comparison between 
DENV2 infected HuH-7 cells in a normoxia control sample and the hypoxic test sample. 





AGT Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) -1.25 0.7247 
AKT1 V-akt murine thymoma viral oncogene homolog 1 -1.07 0.7115 
ATF1 Activating transcription factor 1 -1.59 0.0396 
BCL10 B-cell CLL/lymphoma 10 -1.19 0.3704 
BCL3 B-cell CLL/lymphoma 3 -1.99 0.3764 
CFB Complement factor B -1.39 0.8275 
BIRC2 Baculoviral IAP repeat-containing 2 -1.65 0.4748 
NOD1 Nucleotide-binding oligomerization domain containing 1 -1.80 0.1412 
CASP1 Caspase 1, apoptosis-related cysteine peptidase -1.38 0.5480 
CASP8 Caspase 8, apoptosis-related cysteine peptidase -1.24 0.5559 
CCL2 Chemokine (C-C motif) ligand 2 1.42 0.4402 
CD40 CD40 molecule, TNF receptor superfamily member 5 3.24 0.3844 
CFLAR CASP8 and FADD-like apoptosis regulator -1.96 0.0763 
CHUK Conserved helix-loop-helix ubiquitous kinase -2.74 0.1603 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 1.93 0.2203 
CSF3 Colony stimulating factor 3 (granulocyte) -1.07 0.8261 
SLC44A2 Solute carrier family 44, member 2 -4.91 0.0670 
EDARADD EDAR-associated death domain -1.92 0.1686 
LPAR1 Lysophosphatidic acid receptor 1 -1.08 0.9863 
EGR1 Early growth response 1 -4.88 0.0929 
ELK1 ELK1, member of ETS oncogene family -1.55 0.4172 
F2R Coagulation factor II (thrombin) receptor -2.43 0.2146 
FADD Fas (TNFRSF6)-associated via death domain -2.97 0.1599 
FASLG Fas ligand (TNF superfamily, member 6) 1.19 0.5231 
FOS V-fos FBJ murine osteosarcoma viral oncogene homolog -1.39 0.4525 
GJA1 Gap junction protein, alpha 1, 43kDa -1.52 0.4339 
HMOX1 Heme oxygenase (decycling) 1 3.67 0.3314 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B -2.23 0.2998 
ICAM1 Intercellular adhesion molecule 1 -1.18 0.6301 
IFNA1* Interferon, alpha 1 37.88 0.0254 
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IFNB1* Interferon, beta 1, fibroblast 21.61 0.0432 
IFNG Interferon, gamma 3.65 0.0436 
IKBKB 
Inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta isoform 
3.05 0.0052 
IKBKE* 
Inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase epsilon isoform 
6.03 0.0376 
IKBKG 
Inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma isoform 
3.97 0.0006 
IL10 Interleukin 10 -1.76 0.4198 
IL1A Interleukin 1, alpha 1.24 0.5880 
IL1B Interleukin 1, beta -1.28 0.5140 
IL1R1 Interleukin 1 receptor, type I -1.92 0.1257 
IL6 Interleukin 6 (interferon, beta 2) -2.16 0.1337 
IL8 Interleukin 8 -2.26 0.1484 
IRAK1 Interleukin-1 receptor-associated kinase 1 -2.39 0.0982 
IRAK2 Interleukin-1 receptor-associated kinase 2 -2.19 0.3108 
JUN Jun oncogene -1.71 0.3194 
LTA Lymphotoxin alpha (TNF superfamily, member 1) -1.25 0.6087 
LTBR Lymphotoxin beta receptor (TNFR superfamily, member 3) -1.94 0.3007 
MALT1 Mucosa associated lymphoid tissue lymphoma translocation gene 1 1.06 0.8619 
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 -1.65 0.4887 
MYD88 Myeloid differentiation primary response gene (88) -2.08 0.1140 
NLRP12 NLR family, pyrin domain containing 12 2.45 0.6149 
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 -1.99 0.1748 
NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 -7.08 0.0505 
NFKBIA 




Protein phosphatase 1A (formerly 2C), magnesium-dependent, 
alpha isoform 
-1.33 0.0574 
RAF1 V-raf-1 murine leukemia viral oncogene homolog 1 -1.37 0.4223 
REL V-rel reticuloendotheliosis viral oncogene homolog (avian) -1.22 0.5332 
RELA V-rel reticuloendotheliosis viral oncogene homolog A (avian) -2.56 0.1292 
RELB V-rel reticuloendotheliosis viral oncogene homolog B -4.02 0.1579 
TRIM13 Tripartite motif-containing 13 1.85 0.4507 
RHOA Ras homolog gene family, member A 1.27 0.5798 
RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase 1 -2.30 0.0163 
SLC20A1 Solute carrier family 20 (phosphate transporter), member 1 1.43 0.1607 
STAT1 Signal transducer and activator of transcription 1, 91kDa -3.70 0.0024 
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TBK1 TANK-binding kinase 1 1.08 0.6698 
TICAM2 Toll-like receptor adaptor molecule 2 2.20 0.0897 
TLR1 Toll-like receptor 1 1.41 0.2024 
TLR2 Toll-like receptor 2 1.01 0.9911 
TLR3 Toll-like receptor 3 1.27 0.5134 
TLR4 Toll-like receptor 4 -1.36 0.3938 
TLR6 Toll-like receptor 6 2.58 0.2677 
TLR7 Toll-like receptor 7 -1.40 0.6063 
TLR8 Toll-like receptor 8 -4.21 0.3469 
TLR9 Toll-like receptor 9 -1.04 0.7585 
TMED4 Transmembrane emp24 protein transport domain containing 4 1.50 0.2678 
TNF Tumor necrosis factor (TNF superfamily, member 2) -2.71 0.0941 
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 -2.43 0.2140 
TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a 1.11 0.5575 
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b -1.17 0.5549 
TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A 1.37 0.4047 
CD27 CD27 molecule -1.73 0.1076 
TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 -1.57 0.3762 
TNFSF14 Tumor necrosis factor (ligand) superfamily, member 14 4.10 0.1911 
TRADD TNFRSF1A-associated via death domain -1.34 0.8268 
TICAM1 Toll-like receptor adaptor molecule 1 -1.10 0.7701 
B2M Beta-2-microglobulin -1.77 0.2368 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 -1.09 0.7324 
RPL13A Ribosomal protein L13a -1.14 0.7257 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 2.63 0.0822 
ACTB Actin, beta -1.20 0.6700 
 



































































Figure 6.4: PCR array analysis of NF-kB transcript library. A) The difference in 
expression of different gene transcripts of the NF-kB library is shown in a 3D 
representation where the difference in expression is derived by comparison of 
cellular hypoxic state and normal cellular state of DENV2-infected HuH-7 cells. B) 
The significance of each expression is represented by a volcano plot which shows a 
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The direct effect of cellular hypoxia on DENV2 replication demonstrated in this work 
is the first to be reported in the field of DENV research.  Hypoxia is defined as a 
condition where oxygen is deficient in a habitat or a body part. Hypoxia could occur 
within any living organism when the oxygen (O2) concentration falls below 
physiological levels in spite of adequate blood perfusion. In response, various 
effector mechanisms are triggered: from individual cellular responses to regulation 
via combinatorial interactions at the systemic level. O2 sensing triggers the activation 
of signalling networks that control the expression of various genes, allowing the cells 
to adapt and survive in a hypoxic environment (Figure 7.1). 
 
Some of the established gene expression processes that are activated when cells 
are exposed to hypoxic conditions include the activation of angiogenic processes and 
anaerobic glycolysis, all of which are aimed at promoting cellular proliferation 
[Carmeliet et al., 1998]. This was demonstrated in this study where increased cell 
proliferation was observed for alamarBlue® cell viability assay of HuH-7 cells which 
were maintained in hypoxic growth media (Figure 5.3). 
 
The predominant and well studied O2 adaptive response would be the activation of 
the transcriptional complex, hypoxia-inducible factor (HIF) [Semenza, 2000]. In the 
cell, the sensing of changes in O2 availability is governed by a group of enzymes that 
directly control the cellular response to low O2 by destabilizing the alpha subunits of 
the hypoxia-inducible factor (HIF), the master transcriptional regulator of the hypoxic 









Figure 7.1: The regulation of hypoxia-inducible factor transcription complex. The regulation of 
HIF transcription is dependent on the availability of oxygen molecules to carry out 
hydroxylation of the HIF-α subunits which prevents the binding of its co-activator p300 as well 
as proteasomal degradation via ubiquitination. (Source: Marx, 2004) 
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Typically, the HIF comprises of one of the three alpha subunit isoforms (HIF1α, 
HIF2α/EPAS1 and HIF3α) as well as the common nuclear translocator beta subunit 
(HIF1β/ARNT) [Gu et al., 1998]. HIF1α and HIF2α are closely related and both 
activate hypoxic response element (HRE)-dependent gene transcription whereas 
HIF3α is the more distantly related isoform and, in certain splicing arrangements, 
encodes for a polypeptide that antagonizes HRE-dependent gene expression 
[Wenger, 2002]. Extensive studies on HIF1α revealed that the destabilization of the 
HIFα subunit is O2-dependent and is carried out at the post-transcriptional stage by 
the hydroxylation of its proline (Pro) or asparagine (Asn) residues (Figure 7.1 and 
7.2) [Ivan et al., 2001; Lando et al., 2002]. 
 
In an O2 rich environment, HIF1α exist as a short-lived protein with very low 
expression levels [Huang et al., 1998]. This is due to the presence of an oxygen-
dependent degradation domain (ODDD) within the HIF1α subunit that limits 
expression of HIF1α by means of ubiquitination and proteasomal degradation 
[Salceda and Caro, 1997]. In an O2 abundant environment, hydroxylation of two 
proline residues (Pro402 and Pro564) within the ODDD triggers the binding of the von 
Hippel-Lindau tumour suppressor (pVHL) to HIF1α (Figure 7.2). pVHL functions as 
an ubiquitin E3 ligase, and when bound to the hydroxylated proline (Hyp402 and 
Hyp564) allows for proteasomal targeting of HIF1α [Maxwell et al., 1999]. 
 
The enzymes responsible for the hydroxylation of the proline residues are known as 
HIF prolyl hydroxylases or prolyl hydroxylase domain containing proteins (PHDs), 
and belong to the Fe(II) and 2-oxoglutarate dependent dioxygenase superfamily of 
proteins, which require O2 as a co-substrate. Hence, this family of enzymes acts 
predominantly to regulate levels of HIFs (Figure 7.1) [Bruick and McKnight, 2001]. 
Three PHD genes (phd1, phd2 and phd3) have been identified and are expressed 
ubiquitously [Hirsila et al., 2003]. 





Figure 7.2: The proteasomal degradation of hypoxia-inducible factor alpha subunit via 
ubiquitination. The targeting of HIFα is dependent on the binding of von Hippel-Lindau tumour 




) of HIFα. pVHL 
functions as the ubiquitin E3 ligase to mark HIF1α for proteasomal degradation. (Source: 
Zarember and Malech, 2005) 
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Another mode of regulation of the HIF transcriptional complex is through the 
impediment of its transcriptional activity. This is achieved via the hydroxylation of the 
asparagine residue (Asn803) within the C-terminal trans-activation domain (C-TAD) of 
HIF1α by the factor inhibiting HIF (FIH). It has been shown that the hydroxylation of 
Asn803 inhibits the binding of the co-activator p300/CBP, hence disrupting 
transcriptional activity of the HIF transcriptional complex (Figure 7.1 and 7.2) [Mahon 
et al., 2001]. 
 
During the pilot screening assay of the 24 hydroxylases, it was found that the 
silencing of HIF1α inhibitor (HIF1AN) more commonly known as FIH, reduced 
DENV2 replication by > 50% (p-value < 0.0125). This led us to postulate that the 
state of cellular hypoxia could modulate the replication of DENV2. This notion was 
proven further when reduction in DENV2 replication was observed in a hypoxic 
cellular setting induced by means of chemicals that included Co(II)Cl2 and Fe(II)Cl2. 
By creating an O2 deficient micro-environment for the HuH-7 cells, replication of 
DENV2 were found to be significantly reduced by 1000-fold, likely though the 
activation of hypoxic response elements (HREs) by HIFs. To prove this hypothesis, 
HREs in HuH-7 cells were rendered “non-responsive” by treatment with the drug 
chetomin to prevent the binding of the co-activator p300/CBP. Replication of DENV2 
was enhanced when the HREs were rendered inactive.  
 
To further elucidate the mechanism underlying the effect of cellular hypoxia on 
DENV2 replication, different subunits (HIF1α, HIF2α and HIF1β) of the HIF were 
individually silenced with siRNA. When HuH-7 cells were infected with DENV2, it was 
demonstrated that HIF1α was not the subunit that regulated DENV2 replication; 
instead, enhancement was only evident for HuH-7 cells during the knock-down of 
either HIF2α or HIF1β – with the silencing of HIF2α inducing slightly higher levels of 
 
































HIF1α HIF1β HIF2α Expon. (HIF2α) Expon. (HIF1β) Expon. (HIF1α)
 
Figure 7.3: A comparison on the effects of DENV2 replication when different subunits of the 
HIF genes were knocked-down with siRNA. 
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enhancement in DENV2 replication as compared to that of HIF1β alone (Figure 7.3). 
The above observation, together with following downstream work involving the 
double knock-down of HIF1α / HIF1β and HIF2α / HIF1β subunits reconfirmed that 
HIF1α was indeed not involved in the regulation of DENV2 replication: the enhanced 
replication of DENV2 observed with the HIF1α / HIF1β double knock-down was 
attributed to the silencing of HIF1β alone, as reflected by comparable levels of 
enhancement in DENV2 replication as when HIF1β was singly knocked-down.  
 
The double knock-down of HIF2α / HIF1β instead, led to the enhancement of DENV2 
replication with the same extent as when HIF2α was knocked down. This strongly 
suggests that HIF2α is the predominant subunit involved in the hypoxia-inducible 
pathway that regulates DENV2 replication. Hence, if HIF2α and HIF1β were to act 
through independent pathways to modulate DENV2 replication, the silencing of both 
genes concurrently will result in a synergistic effect and induce an enhancement in 
DENV2 replication significantly higher than that of a single knock-down of either 
HIF2α or HIF1β (Figure 7.4A). Alternatively, if HIF2α acts solely via HIF1β to 
modulate DENV2 replication, silencing of either genes or a double knock-down of 
both genes will yield comparable levels of enhancement in DENV2 replication (Figure 
7.4B).  
 
However, the above scenarios do not explain the experimental data: although the 
double knock-down of HIF2α/HIF1β yielded a significantly higher enhancement of 
DENV2 replication as compared to the single knock-down of HIF1β, the level of 
enhancement was not any greater compared to that when HIF2α alone was silenced. 
This seems to suggest the possibility of an alternate nuclear translocator other than 
HIF1β that could transport HIF2α into the nucleus to activate the HREs. Hence, 
silencing of HIF1β is likely to result in a lower enhancement of DENV2 replication as 
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HIF2α could still interact with the alternate nuclear translocator to limit DENV2 
replication (Figure 7.4C). However, as the level of enhancement in DENV2 
replication was only slightly lower compared to the knock-down of HIF2α/HIF1β or 
HIF2α alone, it strongly suggests that HIF2α acts predominantly but not solely via 
HIF1β in HuH-7 cells to regulate DENV2 replication (Figure 7.4C).   
 
The significance of HIF2α/HIF1β in DENV2 replication could be further supported via 
the silencing of the HIF2α and / or HIF1β genes under hypoxic conditions. Since the 
state of cellular hypoxia significantly limits DENV2 replication, it will important for us 
to demonstrate that silencing of the HIF2α/HIF1β genes in HuH-7 cells while treating 
with Co(II)Cl2 and Fe(II)Cl2, individually or concurrently could reverse the reduced 
DENV2 replication phenomenon observed under hypoxic conditions. This aspect is 
currently investigated in our laboratory.  
 
Nevertheless, it is important to note that HIF2α tends to be over-expressed in cell 
lines derived from the hepatic and macrophage lineage compared to other cell lines 
which predominately expresses HIF1α [Talks et al., 2000]. Hence, a cell line that 
expresses comparable levels of HIF1α and HIF2α that is permissive for DENV 
replication may be necessary to evaluate the importance of the HIF1α in the 
regulation of the HIF pathway and its effect on DENV replication. 
 








Figure 7.4A: An illustration of HIF2α and HIF1β acting independently in the hypoxia-
inducible pathway to modulate DENV2 replication: the effect of HIF2α and/or HIF1β 
knock-down on the regulation of DENV2 replication. X and Y are representative of 
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Figure 7.4B: An illustration of HIF2α acting solely via HIF1β in the hypoxia-inducible 
pathway to modulate DENV2 replication: the effect of HIF2α and/or HIF1β knock-
down on the regulation of DENV2 replication.  
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Figure 7.4C: An illustration of HIF2α acting via an alternative pathway other than 
HIF1β in the hypoxia-inducible pathway to modulate DENV2 replication: the effect of 
HIF2α and/or HIF1β knock-down on the regulation of DENV2 replication. X is 

















 X HIF2α  X 
HIF2α 
HIF1β HIF2α HIF1β 
 X HIF2α  X 
HIF2α 
HIF1β HIF2α HIF1β 
 X HIF2α  X 
HIF2α 
HIF1β HIF2α HIF1β 





Chapter 7: Discussion 
 97 
 
Our results also suggested that the regulatory effect of HIFs on DENV2 replication 
could be unidirectional since the replication of DENV2 in HuH-7 cells (normal O2 
environment) did not appear to cause any significant changes to both the transcript 
and protein levels of HIF1α and HIF2α subunits. Alternatively, infection by DENV2 
could induce a feedback signal to increase expression of HIFs and subsequently 
activate HREs. Notably, activating the HIF pathway was not one of the defence 
mechanisms employed by the virus to persist and replicate within the HuH-7 cells. 
 
A local hypoxic cellular/tissue environment has also been shown to promote cellular 
secretion of inflammatory chemokines that attract neutrophils and monocytes in 
response to an infection or tissue trauma [Cramer et al., 2003]. More importantly, the 
state of hypoxia has been linked to innate immunity by activation of the NF-κB 
pathway [Rius et al., 2008]. Hence, it is possible that the regulatory effects of cellular 
hypoxia on DENV2 replication could be mediated via NF-κB- activated inflammatory 
responses (Figure 7.5). 
 
Results from the real-time qRT-PCR analysis of the 84 genes implicated in the NF-κB 
pathway revealed three prominent and significant differences in the expression 
profile of the 84 genes achieved during DENV2 infection under normoxia versus 
hypoxic states. The inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase epsilon (IKBKE) had a 6-fold increase in expression while a 37-fold and 21-
fold increase was observed for interferon alpha 1 (IFNA1) and interferon beta 1 
(IFNB1) expression, respectively. 
 
IKBKE also known as IκB kinase (IKK)-related kinases epsilon (IKKε), is a member of 
oncogenic kinase of the IKK family. The role of IKKε along with other IKKs is to 
phosphorylate the inhibitors of NF-κB (IκBs). Subsequent dissociation of the IκB from 










Figure 7.5: An overview on the possible relation between the state of cellular hypoxia and the 
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the NF-κB complex ultimately leads to degradation of the IkB and activation of the 
NF-κB pathway (Appendix I: Activation and Regulation of NF-kB Pathway). NF-κB 
has been known to regulate the transcription of a large number of genes involved in 
immune and inflammatory responses. The activation of NF-κB activation also plays 
an important role in the antiviral response through the induction of interferon genes 
[Boehm et al., 1997; Stark et al., 1998]. Type I Interferons (IFNs) are well-
characterized components of the host innate immunity which are rapidly induced in 
response to a viral infection by interferon regulatory factors (IRFs) [Wathelet et al., 
1998]. Links between DENV and IFNs have already been documented, where the 
replication of DENV could inhibit the signalling cascade of IFNA1 thereby producing 
resistance to the anti-viral effects of IFNA1 (Jones et al., 2005). 
 
It has been shown that expression of Type I IFNs in early viral infection is stimulated 
by IRF-3 and expression of other Type I IFNs that are not induced in the early 
stages, by IRF-7 [Sato et al., 2000]. In another work presented by Sharma et al. 
(2003), expression of Type I IFNs through the activation of IKKε and TANK binding 
kinase 1 (TBK-1) was able to inhibit replication of vesicular stomatitis virus (VSV). 
The results from our real-time qRT-PCR array are in accordance to the above work 
conducted with VSV whereby the state of cellular hypoxia notably induced an up-
regulation of IKKε in HuH-7 cells. Likely, the up-regulation of IKKε could result in 
degradation of IκB to allow activation of NF-κB, hence inducing increased production 
of IFNA1 and IFNB1. Alternatively, up-regulation of IKKε could also lead to increased 
IFNA1 and IFNB1 production by interacting directly with IRF-3 or IRF-7 (Appendix II: 
Production and Signaling of Type I Interferon). 
 
Since the real-time qRT-PCR array analysis of genes related to NF-κB serves only to 
provide a general screen of the possible candidates that could be involved in 
modulating the replication of DENV2 during the state of cellular hypoxia via the 
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inflammatory pathway, future studies are required to fully decipher the mechanistic 
role of IKKε in the modulation of DENV2 replication under hypoxic conditions. 
Assessing the regulation of DENV2 replication with the silencing of the IKKε gene 
under hypoxic conditions (Co(II)Cl2 and Fe(II)Cl2 treatment) in HuH-7 cells would be 
an elegant way to demonstrate the significance of IKKε gene in DENV2 replication.   
 
In the field of oncology research, the state of hypoxia has long been an area of 
intense research since it is believed that the microenvironment of malignant tumours 
is one which is constantly in need of O2 due to the anarchic proliferation of cancer 
cells [Bocci et al., 2005]. Active expression of HREs stimulates angiogenic processes 
which in turn increase blood perfusion into the tumour, bringing about active tumour 
metabolism by increasing transport of glucose for glycolytic pathway to maintain 
constant ATP production [Semenza, 2003]. This hypothesis has been further 
supported by the fact that overexpression of HIF1α has been found in various human 
cancers [Zhong et al., 1999]. With several researches proving that the inhibition of 
HIF1α could impair tumour growth, the modulation of HIFs has been deemed as a 
good strategy for the treatment of hypoxic tumours [Carmeliet et al., 1998; Chen et 
al., 2003]. To date, several anti-cancer therapeutics targeting the hypoxia pathway 
have been developed with majority of the candidates already showing inhibition of 
tumour growth in animal models [Benizir et al., 2008]. 
 
In the field of viral research, Hwang et al (2006) made the seminal observation that 
hypoxic conditions inhibited VSV replication. Although follow-up expression profiling 
did exhibit increased expression of IFNB1, the mechanism of IFNB1 upregulation 
was not determined.  DENV proteins NS2A, NS4A and NS4B have shown to render 
the host anti-viral response ineffective by decreasing the Type I IFN signalling 
pathways through the inactivation of STAT1 and STAT2 [Munoz-Jordan et al., 2003; 
Jones et al., 2005]. This effectively prevents the expression of IFN-responsive genes, 
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among which is IRF7 that initiates the transcription of a second wave of Type I IFNs 
(Figure 7.6) [Honda et al., 2005]. Hence, it is undeniable that the inflammatory 
pathway, via IFN signaling plays an important role in limiting viral persistence and 
replication within the host.  
 
In this study, we have demonstrated that DENV2 replication in HUH-7 cells can be 
limited under hypoxic conditions, possibly via the activation of the NF-κB 
inflammatory pathway. Future work will be directed towards elucidating the specific 
mechanism of NF-kB activation by HIFs, as well as the involvement of IKKε and the 
downstream production of IFNs in modulating DENV replication under hypoxic 
cellular environments. Hypoxia mimics could possibly become drug leads for anti-
viral strategy against DENV infections. 
 
 





In conclusion, we have successfully developed a highly specific and sensitive 384-
well high-throughput screening platform based on the principles of RNAi, coupled to 
immunofluorescence assay. The versatility of the developed screening platform 
meant that potential host factors from different genomic libraries could be screened 
rapidly. 
 
With the application of the platform on a small library of human protein hydroxylases, 
a candidate protein - the inhibitor of alpha subunit hypoxia-inducible factor (HIF1AN) 
– was found to significantly reduce DENV2 replication in HuH-7 cells. This 
observation was subsequently validated by the use of hypoxia mimics, Co(II)Cl2 and 
Fe(II)Cl2 as well as chetomin, a drug which specifically inhibits the activation of the 
hypoxia-inducible pathway. It was also shown in this study for the first time, that 
replication of DENV2 in HuH-7 cells could be modulated via the hypoxic pathway by 
hypoxia-inducible factors (HIFs). 
 
Finally, understanding the mechanism of HIFs modulation on DENV2 replication in 
HuH-7 cells was achieved through a PCR array that targets the transcriptional 
expression levels of candidates centred on the NF-kB pathway. This latter study 
revealed that activation of the hypoxia-inducible pathway in HuH-7 cells led to an up-
regulation in expression of type 1 interferons (α and β) and the inhibitor of kappa light 
polypeptide gene enhancer in B-cells, kinase epsilon (IKBKε). The up-regulation of 
these transcripts could possibly interfere with DENV2 replication in the HuH-7 cells. 
 
The observations in this study have raised the notion of an interesting alternative 
strategy on the development of anti-virals against DENV, since there are on-going 
trials for drugs that combat cancer by modulating the hypoxia-inducible pathway. 
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However, this study is only at a preliminary stage and further work must be 
conducted to fully elucidate the mechanisms underlying the modulation of DENV2 
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Figure: The regulation and activation of NF-κB pathway. Activation of NF-κB is 
predominantely achieved through a IKK-dependent pathway where IkB, the main inhibitor of 
NF-κB is phosphorylated by a multi-unit protein complex which includes IKK. The release of 
the NF-κB complex then allows it to relocate to the nucleus for activation of downstream 
genes. (Source: Perkins, 2007) 
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Figure: The production and signaling of type I interferon. Type I IFNs are transcriptionally 
regulated, and are induced following recognition of pathogen components during infection by 
various host pattern recognition receptors. There are three main pathways leading to the 
production of Type I IFN. The RIG-I pathway is activated upon infection by RNA viruses. The 
second pathway involves the adaptor protein TRIF which is recruited by TLR3 and TLR4. The 
last pathway is triggered by TLR7/8 and TLR9 leading to the activation of the transcription 
factor IRF7. Following their production, Type I IFNs trigger antiviral responses by binding to a 
common receptor (IFNAR). IFNα/β binding to IFNAR stimulates the JAK1-STAT pathway 
leading to the assembly of the ISGF3 complex which is composed of STAT1-STAT2 dimers 
and IRF9. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-
stimulated genes to regulate their expression. Among these genes is IRF7 which initiates the 
transcription of a second wave of Type I IFNs. This autocrine/paracrine feed-back allows 
Type I IFNs to create an anti-viral state in surrounding cells. (Source: InvivoGen) 
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APPENDIX III: MATERIALS FOR CELL CULTURE 
 
A) Growth Media, DMEM for HuH-7 cells. 
Items Amount Source 
DMEM 1 packet (1X) Sigma, USA 
Sodium bicarbonate 2.0 g Merck, Germany 
Fetal Calf Serum 100.0 mL (10%) or 20.0 mL (2%) Hyclone, USA 
RO Water 900.0 mL (10%) or 980.0 mL (2%) Milli-Q water system (Millipore) 
 
B) Growth media, RPMI-1640 for BHK cells. 
Items Amount Source 
RPMI-1640 1 packet (1X) Sigma, USA 
Sodium bicarbonate 2.0 g Merck, Germany 
Fetal Calf Serum 100.0 mL (10%) or 980.0 mL (2%) Hyclone, USA 
RO Water 900.0 mL (10%) or 980.0 mL (2%) Milli-Q water system (Millipore) 
 
C) Growth media, L15 for C6/36 cells. 
Items Amount Source 
L15 1 packet (1X) Sigma, USA 
Sodium bicarbonate 2.0 g Merck, Germany 
Fetal Calf Serum 100.0 mL (10%) or 980.0 mL (2%) Hyclone, USA 
RO Water 900.0 mL (10%) or 980.0 mL (2%) Milli-Q water system (Millipore) 
 
D) Phosphate Buffered Saline (PBS) 
Items Amount (g) Source 
NaCl 8.0 Merck, Germany 
KCl 0.2 Merck, Germany 
Na2HPO4 1.2 Merck, Germany 
KH2PO4 0.2 Merck, Germany 
 
The above materials were dissolved in 1 liter of RO water. The pH was adjusted to 
pH 7.3 using either 1M HCL or 1M NaOH. The solution was sterilized at 15 Ib/in2 
(1kg/cm2) pressure for 20 minutes. Storage was at 4°C in a refrigerator.  
 
E) Trypsin-Versene (ATV) Solution (10X concentrate) 
Items Amount Source 
NaCl 80.0g Merck, Germany 
KCl 4.0 g Merck, Germany 
D-glucose 10.0 g Analar, UK 
NaHCO3 5.8 g Merck, Germany 
Trypsin 5.0 g GIBCO, New Zealand 
Versene (EDTA) 2.0 g Sigma, USA 
RO Water 1000.0 mL Milli-Q water system (Millipore) 
 
The mixture was heated to 37°C with occasional shaking for three to four hours to 
dissolve the trypsin. The solution was then sterilized by filtration through a 0.22µm 
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filter unit (Nalgene). To use, 10mL of this solution was added to 90mL of RO water to 
give 1X ATV solution. 
 
F) Overlay Media for BHK cells 
Items Amount Source 
RPMI-1640 1 packet (1X) Sigma, USA 
Sodium bicarbonate 2.0 g Merck, Germany 
Fetal Calf Serum 20.0 mL Hyclone, USA 
RO Water 480.0 mL Milli-Q water system (Millipore) 
1% Carboxymethylcellulose 500.0 mL Behring Diagnostic, USA 
 
G) 0.5% Crystal Violet / 25% Formaldehyde Solution 
Items Amount Source 
Crystal Violet 5.0 g Sigma, USA 
37% formaldehyde solution 300.0 mL Merck, Germany 
PBS 200.0 mL See appendix IIIC 
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APPENDIX IV: MATERIALS FOR WESTERN BLOT 
 
A) 10X Laemmli Electrolyte Buffer (Running Buffer) 
Item Amount Source 
Tris base 30.0 g Promega, USA 
Glycine 144.0 g Sigma, USA 
Sodium Dodecyl Sulphate 10.0 g Sigma, USA 
RO Water 1000.0 mL Milli-Q water system (Millipore) 
 
10X Laemmli electrolyte buffer was diluted to 1X Laemmli electrolyte buffer solution 
before use by adding 9 parts of RO Water to 1 part of 10X Laemmli electrolyte buffer. 
 
B) 1X Towbin’s Buffer (Transfer Buffer) 
Item Amount Source 
Tris base 3.03 g Sigma, USA 
Glycine 14.41 g Sigma, USA 
Methanol 200.00 mL Merck, Germany 
RO Water 800.00 mL Milli-Q water system (Millipore) 
 
C) Blocking Solution 
Item Amount Source 
Blocker A 4.0 mL Western Breeze Kit (Invitrogen, USA) 
Blocker B 2.0 mL Western Breeze Kit (Invitrogen, USA) 
RO Water 14.0mL Milli-Q water system (Millipore) 
 
Blocking solution was also used as the diluents for antibody.  
 
D) Antibody Wash Solution 
Item Amount Source 
16X Wash Solution Concentrate 10.0 mL Western Breeze Kit (Invitrogen, USA) 
RO Water 150.0 mL Milli-Q water system (Millipore) 
 
E) 3X Laemmli Loading Buffer (100mL) 
Item Amount Source 
1M Tris-Cl pH 6.8 24.0 mL Promega, USA 
20% SDS 30.0 mL Sigma, USA 
100% Glycerol (100%) 30.0 mL Sigma, USA 
B-mercaptoethanol 16.0 mL Sigma, USA 
Bromophenol blue 0.06 g Sigma, USA 
 
3X Laemmli loading buffer was diluted to 1X with sample prior to sample 
denaturation for SDS-PAGE and Western blot.
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APPENDIX IV: FIRZAN ANG, ANDREW PHUI YEW WONG, MARY NG AND 
JUSTIN CHU, VIROLOGY JOURNAL (2010) VOL.7: 24 
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